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Abstract Some individuals with a particular disease-
causing mutation or genotype fail to express most if not all
features of the disease in question, a phenomenon that is
known as ‘reduced (or incomplete) penetrance’. Reduced
penetrance is not uncommon; indeed, there are many
known examples of ‘disease-causing mutations’ that fail to
cause disease in at least a proportion of the individuals who
carry them. Reduced penetrance may therefore explain not
only why genetic diseases are occasionally transmitted
through unaffected parents, but also why healthy individ-
uals can harbour quite large numbers of potentially disad-
vantageous variants in their genomes without suffering any
obvious ill effects. Reduced penetrance can be a function
of the specific mutation(s) involved or of allele dosage.
It may also result from differential allelic expression, copy
number variation or the modulating influence of additional
genetic variants in cis or in trans. The penetrance of some
pathogenic genotypes is known to be age- and/or sex-
dependent. Variable penetrance may also reflect the action
of unlinked modifier genes, epigenetic changes or envi-
ronmental factors. At least in some cases, complete pene-
trance appears to require the presence of one or more
genetic variants at other loci. In this review, we summarize
the evidence for reduced penetrance being a widespread
phenomenon in human genetics and explore some of the
molecular mechanisms that may help to explain this
enigmatic characteristic of human inherited disease.
Introduction
One old conundrum in human genetics is that not everyone
with a given pathological mutation (or mutations) will
eventually develop the disease in question. The proportion
of those individuals harbouring a particular pathogenic
mutation or genotype who exhibit clinical signs of the
associated disorder within a specific and clearly defined
time period is termed the penetrance of that disorder. If this
proportion equals 100 %, the disease and/or disease
genotype(s) are said to show complete penetrance. If not,
they are said to exhibit reduced (or incomplete) penetrance.
Reduced penetrance is likely to be a consequence of the
combination of a variety of different genetic and environ-
mental factors. A classic example is phenylketonuria,
where inactivating mutations in the PAH gene encoding the
enzyme phenylalanine hydroxylase lead to severe intel-
lectual disability in the context of a normal diet, whereas a
life-long phenylalanine-restricted diet makes possible a
relatively healthy life (Blau et al. 2010). Regrettably, few
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other examples of reduced penetrance are as simple, well
understood or clinically manipulable as this one, and the pre-
cise mechanisms by which different factors give rise to reduced
penetrance remain largely unknown (Zlotogora 2003).
In formal terms, penetrance measures the proportion of
individuals in a given population with a specific disease-
associated genotype who also express the corresponding
disease phenotype. Large family/population studies have
traditionally been considered necessary to measure pene-
trance, either for specific mutations/genotypes or as a dis-
ease average. ‘Cascade genetic screening’, whereby
relatives of previously identified carriers are screened both
for the mutation(s) in question and for the presence/
absence of clinical symptoms, is one means to determine
the degree of penetrance for a given genotype (Berge et al.
2008). As we discuss below, large-scale sequencing and
genotyping studies of apparently healthy individuals from
the general population provide a powerful new approach to
understanding the penetrance of pathological mutations/
genotypes. The outcomes of such studies should allow us to
predict how likely it is that a given disease will manifest
itself in an individual who carries a specific genotype.
Reduced penetrance is most obviously evident in dis-
orders that follow an autosomal dominant mode of inher-
itance. In these instances, reduced penetrance is a
characteristic of the underlying mutation, rather than a
genotype. However, reduced penetrance can also occur in
autosomal recessive disorders where one and the same
mutation can have different phenotypic effects, depending
at least in part upon the second disease allele present.
Irrespective of the mode of inheritance, in most cases
penetrance is likely to be a function of the specific muta-
tion(s) involved. Thus, in some conditions normally char-
acterized by an autosomal dominant mode of inheritance,
two incompletely penetrant (or otherwise non-penetrant)
alleles may act in recessive fashion while mimicking the
normal dominant form of the disease (e.g. Grundy et al.
1991; Croxen et al. 2002; Kowalewski et al. 2007; Cast-
aman et al. 2007; Rossetti et al. 2009; Vujic et al. 2010;
Schaaf et al. 2011a). For a dominantly inherited condition,
one consequence of reduced penetrance is that the clinical
phenotype may not be evident in one generation, but can
nevertheless still be transmitted (through an apparently
unaffected parent) to subsequent generations where it again
manifests itself; specimen examples of this from clinical
practice include hereditary hyperekplexia (Kwok et al.
2001), cherubism (Preda et al. 2010), retinitis pigmentosa
(Rio Frio et al. 2009), rhabdoid tumour predisposition
syndrome (Ammerlaan et al. 2008), autism spectrum dis-
order (Fujita-Jimbo et al. 2012) and hypercholesterolaemia
(Garcia–Garcia et al. 2011). For all the above reasons,
reduced penetrance presents a major challenge to genetic
counsellors attempting to interpret the medical history of a
patient’s family to quantify the disease risk to the patient’s
offspring (Emery 1986; Otto and Maestrelli 2000).
Reduced penetrance is not uncommon; indeed, there are
many known examples of bona fide disease-causing vari-
ants or genotypes that fail to cause disease in at least a
proportion of individuals who carry them (Zlotogora 2003;
Waalen and Beutler 2009). By definition, penetrance refers
to the black and white issue of whether the clinical phe-
notype associated with a certain genotype is present or not.
We routinely distinguish it from variable expressivity
which refers to the degree of variation of the clinical
phenotype in those individuals with a particular genotype.
Although, in principle, penetrance and expressivity are
distinct terms with specific meanings (depending upon the
way a given clinical phenotype is defined), in practice they
are closely inter-related and likely to manifest via similar
mechanisms. We also distinguish reduced penetrance from
small effect size. Thus, most carriers of the risk alleles
discovered by genome-wide association studies (GWAS)
may never develop the disease in question; this is because
these variants generally only make a small contribution to
the multifactorial aetiology of the condition. To be able
instead to say that the variant is non-penetrant in some
individuals, we require the same variant in other individ-
ual(s) to make the crucial difference between the pheno-
type being manifested or not. In what follows, we shall
focus specifically on the molecular mechanisms that could
account for the phenomenon of reduced penetrance. This
notwithstanding, the discussion of genetic variants that
modulate the expressivity of a particular disease has
sometimes also been deemed appropriate.
In this review, we present the evidence for reduced
penetrance being a widespread phenomenon in human
genetics, evidence that comes not only from a plethora of
case studies of monogenic disorders but also more recently
from the next generation sequencing of entire exomes or
genomes of apparently normal healthy individuals from the
general population. Here, we have attempted to explore the
individual genetic components that contribute to the com-
plexity of primarily monogenic disorders with reduced
penetrance. This notwithstanding, the action of modifier
genes is one of the mechanisms responsible for reduced
penetrance, and one that has increasingly become recog-
nized as blurring the distinction between monogenic con-
ditions and complex disease (Nadeau 2003; Badano and
Katsanis 2003; Sidransky 2006). Finally, we explore some
of the molecular mechanisms which could account for the
reduced penetrance of many human inherited disorders and
provide evidence to support the view that, at least in some
instances, complete penetrance requires the presence of one
or more genetic variants at other loci.
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Deleterious and disease alleles in the general population
In the wake of the sequencing of multiple human genomes,
it has become apparent that healthy individuals can harbour
quite large numbers of potentially disadvantageous variants
without suffering any obvious ill effects (The 1000 Gen-
omes Project Consortium 2010; MacArthur et al. 2012;
Xue et al. 2012; Shen et al. 2013a). The underlying reasons
are likely to be many and varied: thus, the variants may
damage the protein in question but the intact protein may
not be necessary for the health of the carrier; individuals
may be asymptomatic carriers of single-mutant alleles that
could, in homozygosity or compound heterozygosity, cause
recessive disease; the mutation may be dominant but the
clinical phenotype might only be mild and classed as lying
within the range of normal healthy variation; the disorder
might be late in onset with expression being age- or sex-
dependent; or the disorder may require additional genetic
and/or environmental factors for it to manifest clinically.
Assessing the magnitude of the ‘genetic burden’
imposed on the general population by the presence of
deleterious alleles has been a key aim of medical and
population genetics for many decades. With the advent of
large-scale sequencing technologies, it has become possi-
ble to estimate the number of amino acid substitutions in
the human exome that would be predicted in silico to be
damaging (Kryukov et al. 2007; Lohmueller et al. 2008;
Boyko et al. 2008; Goode et al. 2010). However, personal
genome sequences have not only provided estimates of the
number of disease variants carried by each subject (Asan
et al. 2011), but have also given us a glimpse of the likely
complexity of the functional interpretation of such data
(Ashley et al. 2010; Strom and Gorin 2013). More recently,
Tennessen et al. (2012) suggested that 2.3 % of the 13,595
single nucleotide variants carried by the average person
impact upon protein function, involving *313 genes per
human genome. Adopting an alternative approach, Bell
et al. (2011) surveyed 437 genes known to be related to a
recessive Mendelian disease and identified 2.8 mutations
per individual (range 0–7). Taken together, these studies
suggest that individuals typically carry hundreds of mildly
disadvantageous variants and perhaps several tens of
potentially severe disease alleles.
In a pilot study for the 1000 Genomes Project Consor-
tium (2010), we reported the prevalence of disease alleles,
defined by reference to the disease-causing mutations
(DMs) listed in the Human Gene Mutation Database
(HGMD; http://www.hgmd.org; Stenson et al. 2009), in
population samples of African, European and East Asian
origin. These numbers were surprisingly high: 57–80 dis-
ease alleles per individual in a sample of 179 participants.
Moreover, further examination of these data showed that
191 disease alleles were present in the homozygous state in
at least one individual, and hence were not simply present
because their phenotypic/clinical effects had been masked
by a normal allele. Although little phenotypic information
other than sex, ethnicity, place of origin and relationship to
other participants is available for the 1000 Genomes Pro-
ject donors, the Project’s ethical framework requires that
sample donors are non-vulnerable adults who are compe-
tent to consent to participation in the project and hence are
likely to lack any obvious severe disease phenotype.
Instead, we need to seek some other explanation for the
high number of DMs present. One possibility is that the
penetrance of disease alleles and genotypes could be much
lower and more variable than previously realized. Con-
ventionally, most studies of human inherited disease that
have contributed mutation data to HGMD have sought to
identify a disease genotype, given a clinical phenotype
(Cooper et al. 2010). This is a very different scenario from
identifying a phenotype given a (potentially disease asso-
ciated) genotype. Indeed, the former strategy inevitably
avoids the whole issue of penetrance because, by defini-
tion, it focuses exclusively upon those individuals in whom
the mutation of interest has been penetrant. It follows that a
given variant could be genuinely causative in a set of
individuals manifesting a particular disease, yet may also
be present in a set of healthy individuals who differ in any
one of a number of ways to be discussed below.
Since the 1000 Genomes Project Consortium paper was
published in 2010, two further reports have appeared that
served to improve our knowledge of deleterious mutations
in the genomes of apparently healthy individuals. The most
readily recognized deleterious variants in the human gen-
ome are those that disrupt a protein-coding gene, either by
leading to a loss of function (e.g. a nonsense or frameshift
variant) or by altering an amino acid in the encoded protein
(missense variants). The former category of mutation has
been studied by MacArthur et al. (2012) who identified
1,285 putative loss-of-function variants (i.e. nonsense
mutations, splice site-disrupting single nucleotide variants,
micro-insertions/micro-deletions, etc.) in the genome
sequences of 185 humans from the 1000 Genomes Project.
From these data, they estimated that an average human
genome typically contains *100 genuine loss-of-function
variants with *20 genes having both copies inactivated.
Following on from this study, Xue et al. (2012) focused on
missense mutations, ascertaining the numbers of poten-
tially deleterious missense variants in the genomes of
apparently healthy individuals using low-coverage whole-
genome sequence data from 179 individuals in the 1000
Genomes Pilot Project. Each individual was found to carry
281–515 missense substitutions predicted with a high
degree of confidence to be damaging to the gene product,
40–85 of which were present in the homozygous state.
Taken together, these studies suggest that a typical healthy
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individual has about 80 of their genes severely damaged or
inactivated in both copies, further emphasizing the stark
contrast between damage to gene and protein on the one
hand, and damage to health on the other. The 1000 Gen-
omes Project participants also carried 40–110 variants
(3–24 homozygous) classified by HGMD as DMs. Whereas
many of these DMs could conceivably represent disease
attribution errors of some kind, between 0 and 8 DMs per
individual (0–1 homozygous) were predicted to be highly
damaging.
Among the missense DMs, Xue et al. (2012) identified
known pathological variants such as HBB (c.20A[T;
p.Glu7Val), which leads to increased resistance to malaria
in heterozygotes but to sickle cell disease in homozygotes
[confined to Africans (Yoruba, YRI) in whom there were
12 heterozygotes and 1 homozygote]. In addition, Xue
et al. (2012) identified an USH2A variant (c.2138G[C;
p.Gly713Arg), previously reported as being causal for
Usher syndrome type 2, a recessive disorder characterized
by combined deafness and blindness; three homozygotes
were noted in the YRI. Manual curation of the HGMD-
1000GP overlap revealed the presence of three types of
DM: (1) plausible severe disease-causing variants, (2)
variants convincingly causative for pathological condi-
tions, yet quite compatible with adult life and (3) variants
probably incorrectly assigned as disease causing. After
applying various filtering criteria designed to enrich for
true disease alleles, the list was reduced to 45 candidates
(Xue et al. 2012). Of these putative disease alleles, 34 were
present in the heterozygous state and were deemed likely to
Table 1 Disease variants potentially capable of either causing dominant disease, or causing recessive disease and observed in the homozygous
state, detected in 1000 Genomes Project participants (data from Xue et al. 2012)
Disease (MIM
number)
Inheritance Gene HGVS cDNA
mutation
Protein
alteration
Total
homozygotes
Total
heterozygotes
Comments
Ataxia
telangiectasia
(MIM# 607585)
AR ATM NM_000051.3:
c.4258C[T
p.Leu1420Phe 1 3 Low-penetrance breast
cancer susceptibility
allele
Usher syndrome
type IIA (MIM#
276901)
AR USH2A NM_206933.2:
c.2137G[C
p.Gly713Arg 3 22 Probable complex
pathogenicity; neutral
in YRI?
Nephronophthisis
4 (MIM#
606966)
AR NPHP4 NM_015102.3:
c.2542C[T
p.Arg848Trp 1 2 Growth retardation;
adult-onset renal
disease
Cushing
syndrome
(MIM# 607397)
AR MC2R NM_000529.2:
c.833T[G
p.Phe278Cys 1 10 Hormonal disorder;
variable gender-specific
symptoms; variant
functionally defective
in vitro
Low-
phospholipid-
associated
cholelithiasis
(MIM# 171060)
AR ABCB4 NM_000443.3:
c.2363G[A
p.Arg788Gln 2 9 Adult onset
Cardiomyopathy,
hypertrophic
(MIM# 115197)
AD MYBPC3 NM_000256.3:
c.1519G[A
p.Gly507Arg 0 2 Late onset; incomplete
penetrance
Glaucoma,
primary open
angle (MIM#
609887)
AD WDR36 NM_139281.2:
c.1586G[A
p.Arg529Gln 0 1 Adult onset; variant
functionally defective
in vitro
Colorectal cancer,
nonpolyposis
(MIM# 609310)
AD MLH1 NM_000249.3:
c.1742C[T
p.Pro581Leu 0 1 Adult onset; variant
functionally defective
in vitro
Renal cell
carcinoma
(MIM# 144700)
AD FLCN NM_144997.5:
c.715C[T
p.Arg239Cys 0 1 Late onset
Heparin cofactor
2 deficiency
(MIM# 612356)
AD SERPIND1 NM_000185.3:
c.623G[A
p.Arg208His 0 2 Deficiency state, but no
overt disease; risk factor
for thrombophilia
Lp(a) deficiency
(MIM# 152200)
AD LPA NM_005577.2:
c.4289?1G[A
essential
splice site
0 5 Late onset; risk factor for
heart disease
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be present in asymptomatic carriers. Among the remaining
11 (Table 1), the 6 linked to dominant disorders were
explicable in terms of either late onset (e.g. Gly507Arg in
MYBPC3) or covert disease (Arg208His in SERPIND1). In
similar vein, the presence of homozygotes for four of the
five recessive disorders could be explicable in terms of late
onset and/or reduced penetrance of disease. The USH2A
mutation (Gly713Arg) was, however, intriguing: this var-
iant was predicted to be damaging to the protein, and
pathogenic in some populations but not in others (e.g.
YRI). One explanation put forward to explain this apparent
contradiction was that, in the YRI population, the USH2A
locus is subject to copy number variation (Matsuzaki et al.
2009) that could provide functional complementation of
the mutant gene. In the majority of cases, however, the
most likely explanation for the absence of disease at the
time of recruitment was considered to be the probable late
onset of disease, although clinical penetrance was often
variable, and some phenotypes, such as loose anagen hair
syndrome [caused by Glu337Lys in KRT75 (MIM
600628)], might not even be regarded as ‘‘diseases’’ sensu
stricto. These factors notwithstanding, the findings of Xue
et al. (2012) suggest that incidental findings which are
potentially relevant to health and well-being might be made
in as many as 11 % of individuals sequenced.
Reduced penetrance is one of several possible explana-
tions for why some variants of putative pathological sig-
nificance, listed in HGMD and/or Locus-specific Mutation
Databases, nevertheless occur in apparently healthy indi-
viduals (Ashley et al. 2010; Bell et al. 2011; Xue et al. 2012;
Golbus et al. 2012; Wang et al. 2013a; Kenna et al. 2013;
Shen et al. 2013a). It is not hard to see why reduced pene-
trance might be much more common among described
mutations than originally thought: whereas known patho-
logical mutations have almost invariably been identified
through retrospective analyses of families or well-defined
groups of clinically symptomatic patients, relatively few
prospective studies of asymptomatic carriers have so far
been performed to derive estimates of penetrance (e.g.
Jensen et al. 2013; Mavaddat et al. 2013). Indeed, estab-
lishing that a specific mutation identified in a particular
patient with a given disease is the pathological lesion
responsible for that individual’s clinical phenotype does not
allow one automatically to judge whether this mutant
genotype will invariably give rise to the same clinical phe-
notype in all other individuals harbouring it. This can only
be established (or refuted) empirically by comprehensive,
ideally prospective, studies of the genotype in question.
One fairly obvious reason why comparing the output of
genome sequencing projects (e.g. the 1000 Genomes Pro-
ject) with a comprehensive database of putatively patho-
logical mutations (e.g. HGMD) is likely to generate a
considerable number of potentially pathogenic mutations in
the general population, is that many such mutations are
quite frequent in the population at large. In particular,
carrier frequencies for mutations underlying recessive
conditions can often be quite high. Thus, the ABCA4
Gly863Ala mutation causing Stargardt disease has a carrier
frequency of 1.8 % in Europe (Maugeri et al. 2002), the
GJB2 35delG mutation causing congenital deafness has a
carrier frequency of 2.9 % in southern Europe (Gasparini
et al. 2000), the ERCC8 Tyr322Term mutation causing
Cockayne syndrome has a carrier frequency of 6.8 % in
Israeli Christian Arabs (Khayat et al. 2010) and the SPG7
Ala510Val mutation associated with adult-onset neuroge-
netic disease has a carrier frequency of 3–4 % in the UK
population (Roxburgh et al. 2013). Disease allele fre-
quencies can be as high as 10 % in certain ethnic groups,
e.g. Jews (Zlotogora et al. 2007; Ostrer and Skorecki
2013). A recent screen of the Korean population for 20
common mutations contributing to six autosomal recessive
disorders yielded a combined carrier frequency of 6.7 %
(Song et al. 2012). Screening an ethnically diverse US popu-
lation sample (N = 364,890) for 87 different CFTR mutations
responsible for causing cystic fibrosis yielded a combined
carrier frequency of 2.6 % (Rohlfs et al. 2011). As part of the
NHLBI-Go Exome Sequencing Project, a screen of 5,400
individuals from the general population for variants in eight
long QT syndrome genes yielded a total of 33 different mis-
sense mutations (affecting 173 alleles), representing a carrier
frequency of 3.2 % (Refsgaard et al. 2012). A similar screen
for cardiomyopathy-associated gene variants yielded com-
bined carrier frequencies for mutations reported to be disease
associated of 25 % (1,474/5,810) for hypertrophic cardio-
myopathy, 15 % (963/6,334) for dilated cardiomyopathy and
(22 %) 1,393/6,359 for arrhythmogenic right ventricular
cardiomyopathy (Andreasen et al. 2013); the high number of
detected cardiomyopathy-associated gene variants suggests,
however, that many are only modest disease modifiers or even
non-pathogenic. Nishiguchi and Rivolta (2012) screened 46
complete genome sequences from the general population for
mutations in 106 genes associated with recessively inherited
retinal degeneration and identified null mutations in ten
individuals (22 %). Finally, a routine screen of 23,453 indi-
viduals for 417 pathogenic mutations associated with a total of
108 recessive diseases concluded that 24 % of individuals
were carriers of at least one disorder, whilst 5.2 % were car-
riers of two or more disorders (Lazarin et al. 2013). Clearly,
there is a veritable abundance of actual and potential patho-
logical variants segregating in the general population.
The examples that we cite in the text that follows and in
the accompanying tables are by no means comprehensive
and have been provided simply to illustrate the many and
varied mechanisms that are already known to underlie the
phenomenon of reduced penetrance in relation to clinical
disorders. However, these examples also demonstrate that
Hum Genet (2013) 132:1077–1130 1081
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it is often very hard for authors, diagnosticians and muta-
tion database curators alike to classify the pathogenicity of
identified variants with any degree of certainty. Thus, is a
given missense mutation a bona fide pathological lesion
that exhibits greatly reduced penetrance, or is it essentially
a neutral or near-neutral variant that occasionally finds
itself in cis to other variants that are responsible for con-
ferring the disease phenotype upon the individual con-
cerned, or is it a variant with small effect that is sometimes
present in affected individuals whose major causative
lesions remain unknown?
Incomplete penetrance in dominant and recessive
conditions
A considerable number of autosomal dominant disorders are
characterized by incomplete penetrance. Well-studied
examples include the hair disease monilethrix (KRT86; De
Cruz et al. 2012), congenital cataract (GJA3; Burdon et al.
2004), different types of retinitis pigmentosa (PRPF8 and
PRPF31; Maubaret et al. 2011; Saini et al. 2012), LMNA
mutation-associated muscular phenotypes (Rankin et al.
2008) and long QT syndrome (Giudicessi and Ackerman
2013; Mathias et al. 2013).
One rather well-understood example of incomplete pene-
trance of a dominantly inherited mutation is factor V Leiden
(F5, Arg534Gln; Arg506Gln in legacy nomenclature; rs6025)
which occurs at polymorphic frequencies (2–5 %) in European
populations, but is associated with a sixfold increased risk of
venous thrombosis and a two- to threefold increased risk of
pregnancy loss (Kujovich 2011). Despite these very evident
disease associations, the vast majority of factor V Leiden car-
riers appear to be clinically unaffected. This could help to
account for the high frequency of this variant in the general
population, together perhaps with the survival advantage con-
ferred by factor V Leiden carriership in various other clinical
contexts including severe sepsis (Kerlin et al. 2003; van Mens
et al. 2013). In similar vein, the asymptomatic (clinically
covert) state is much more common than the clinically overt
state in several other dominant disorders of haemostasis,
including protein C deficiency (Tait et al. 1995; McColl et al.
1996), protein S deficiency (Dykes et al. 2001), antithrombin
deficiency (Tait et al. 1994; McColl et al. 1996) and von
Willebrand disease (Rodeghiero et al. 1987; Castaman et al.
2003). Thus, in disorders of haemostasis and thrombosis, even
with well-characterized variants that are known to confer a
significantly increased disease risk, the clinical penetrance is
often so low that more healthy individuals carry the variant than
those who actually manifest disease.
Reduced or incomplete penetrance has also been described
for autosomal recessive disorders. Probably the best charac-
terized example of incomplete penetrance in a recessive
disorder is provided by the Cys282Tyr (rs1800562) mutation
in the haemochromatosis (HFE) gene (Beutler 2003). The
Tyr282 homozygous genotype is present in approximately 1 in
200 people of Northern European origin and is responsible for
80–90 % of hereditary haemochromatosis (Weiss 2010;
Rochette et al. 2010). Although Tyr282 homozygosity displays
a relatively high biochemical penetrance (i.e. iron accumula-
tion), its clinical penetrance is low (McCune et al. 2006).
Available data suggest that 38–50 % of Tyr282 homozygotes
develop iron overload and 10–25 % develop some type of
haemochromatosis-associated morbidity (Whitlock et al.
2006). However, these statistics conceal what appears to be a
gender effect: large-scale studies of newly diagnosed Tyr282
homozygotes, in whom liver disease had been specifically
assessed, revealed that disease manifested in 24–43 % of
males, but only 1–14 % of females (Rossi et al. 2008). Various
genetic modifiers have been identified as influencing the
clinical expression of haemochromatosis. These include
mutations in the HAMP, HFE2 and TFR2 genes and poly-
morphisms in the BMP2, BMP4, CYBRD1, HP, LTA, MPO,
TMPRSS6 and TNF genes (Milet et al. 2007; Rochette et al.
2010; Valenti et al. 2012; Pelucchi et al. 2012). In addition,
several environmental modifiers (e.g. diet, alcohol intake) are
also known to affect the penetrance of the HFE genotype.
In another recessive disorder, Gaucher disease, the most
common GBA mutation, Asn370Ser (Asn409Ser in HGVS
nomenclature; rs76763715), is also characterized by low
penetrance and exhibits extensive phenotype heterogeneity
even in the homozygous state (Sibille et al. 1993; Horowitz
et al. 1998; Fairley et al. 2008). However, close examina-
tion of asymptomatic Ser370 homozygotes, serendipitously
diagnosed by prenatal carrier screening, revealed a variety
of previously unidentified disease manifestations indicating
that the clinical penetrance of this disease genotype may be
greater than previously appreciated (Balwani et al. 2010).
Influence of mutation type on penetrance
Clinical penetrance is in part a function of the muta-
tion(s) in question. For a given disease, some causal
mutations may exhibit complete clinical penetrance,
whereas other mutations in the same gene show incomplete
or even very low penetrance. Thus, whereas the penetrance
of the most common CFTR gene lesion, DPhe508
(rs113993960), in cystic fibrosis is very high, the pene-
trance of the CFTR Arg117His (rs78655421) mutation (in
any allele combination) appears to be so low as to call into
question its putative role as a pathological mutation
(Thauvin-Robinet et al. 2009).
As yet, relatively few studies have been performed on
low-penetrance mutations with a view to identifying the
features responsible at the molecular level for their low
1082 Hum Genet (2013) 132:1077–1130
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penetrance. One exception is in retinoblastoma where it has
been found that low-penetrance RB1 mutations tend either
to lead to a reduction in the amount of Rb protein produced
(through promoter or splice site mutations) or yield a
partially functional Rb molecule through missense muta-
tion or in-frame deletion (Onadim et al. 1992; Kratzke
et al. 1994; Bremner et al. 1997; Otterson et al. 1997;
Scheffer et al. 2000; Genuardi et al. 2001; Harbour 2001;
Klutz et al. 2002; Lefe´vre et al. 2002; Valverde et al. 2005;
Sa´nchez-Sa´nchez et al. 2005; Sampieri et al. 2006; Ga´mez-
Pozo et al. 2007; Park et al. 2008; Hung et al. 2011). Of
particular interest is the category of temperature-sensitive
mutations in the Rb pocket domain (DAsn480, Arg661Trp,
Cys712Arg) whose ‘reversible fluctuations’ in a threshold
level of Rb pocket-binding activity could be responsible for
their characteristic low penetrance (Otterson et al. 1999).
On the basis of studies performed to date, it would appear
that a high proportion of RB1 mutations with reduced
penetrance are splice site mutations, although not all splice
site mutations display low penetrance.
Some mutations are associated with specifically reduced
penetrance as compared to other mutations of the same
type in the same gene. For example, BRCA1 Arg1699Gln is
characterized by a cumulative risk of breast or ovarian
cancer by the age of 70 years of only 24 % (Spurdle et al.
2012), much lower than for the average pathogenic BRCA1
mutation (*71 %; van der Kolk et al. 2010). Individuals
with GJB2-associated deafness who harbour two nonsense/
truncating mutations exhibit a much more severe clinical
phenotype, and hence are more likely to come to clinical
attention, than those harbouring two missense mutations
(Azaiez et al. 2004). This serves to illustrate that, in
recessive disorders, the clinical penetrance of one mutation
may be strongly influenced by the nature of the other
mutation in trans. In Ehlers–Danlos syndrome type IV,
however, null COL3A1 mutations tend to exhibit lower
penetrance than missense and splicing mutations (Leistritz
et al. 2011); this is presumably because a faulty gene
product can disrupt the entire triple helical collagen mol-
ecule, whereas a null mutation merely reduces the amount
of normal collagen produced (Arnold and Fertala 2013). In
the same vein, patients with heritable pulmonary arterial
hypertension, due to missense mutations in the BMPR2
gene, present earlier and with more severe disease than
patients harbouring truncating mutations (Austin et al.
2009a). It is thought that the missense mutations are
associated with stable BMPR2 transcripts encoding
BMPR2 protein which exerts a dominant negative effect on
BMP signalling, thereby rendering missense mutations
more detrimental than truncating mutations. The majority
of BMPR2 missense mutations were penetrant prior to the
age of 36 years, whereas the majority of truncating muta-
tions became penetrant only after the age of 36 years
(Austin et al. 2009a). With mutations of the TNFRSF1A
gene causing TNF receptor-associated periodic syndrome,
missense mutations in cysteine residues have been reported
to be more penetrant than missense mutations in non-cys-
teine residues (Aksentijevich et al. 2001; Aganna et al.
2001). Intriguingly, a SOD1 Leu117Val missense mutation
which yields a mutant protein indistinguishable from wild-
type SOD1 (in terms of its activity, stability and folding)
causes amyotrophic lateral sclerosis, but with unusually
low penetrance and slow progression (Synofzik et al. 2012).
Finally, clinical penetrance may vary not only with the
mutation type, but also with the location of the mutation in the
gene/protein (Jackson et al. 1999; Risch et al. 2001; Yatsenko
et al. 2001; van der Werf et al. 2012; Ho et al. 2012).
In autosomal dominant hereditary pancreatitis, the pene-
trance of the PRSS1 Arg122His mutation has been calculated
to be 86 %, whereas that of PRSS1 Ala16Val is of the order of
55–65 % (Grocock et al. 2010; Joergensen et al. 2010). It is
thought that the comparatively low penetrance of this latter
mutation may be related to its particularly mild biochemical
phenotype. The Ala16Val substitution alters the N-terminal
residue of the trypsinogen activation peptide, thereby
increasing the rate of N-terminal processing by chymotrypsin
C by *5.8-fold (Szabo´ and Sahin-To´th 2012). Since the
activation peptide is released during the activation process, the
Ala16Val mutation is absent from active trypsin and hence
cannot influence trypsin function.
Missense mutations in the MEFV gene responsible for
familial Mediterranean fever can differ quite dramatically
in terms of their clinical penetrance. For example,
Met694Val is generally characterized by high penetrance,
whereas both Glu148Gln and Val726Ala exhibit reduced
penetrance (Shohat and Halpern 2011). In this disorder, the
carrier frequency is higher than would be expected from
the prevalence of the disease, suggesting that the pene-
trance of pathogenic MEFV mutations may often be
incomplete in the compound heterozygous state (Gershoni-
Baruch et al. 2002; Zaks et al. 2003; Caglayan et al. 2010;
Camus et al. 2012; Soriano and Manna 2012).
Double missense mutations in cis are not infrequently
encountered in patients with an inherited disease. One of
the two mutations may represent a hypomorphic (i.e. less
functional) allele, as for example with the GLA Asp313Tyr
occurring in cis to the pathogenic Gly411Asp in patients
with Fabry disease (Yasuda et al. 2003). Double missense
mutations in cis may however be associated with a highly
variable clinical phenotype (e.g. MEFV, Pro369Ser/
Arg408Gln as a cause of familial Mediterranean fever;
Ryan et al. 2010). A low-penetrance missense mutation
may be associated with a particularly severe clinical phe-
notype when it occurs in cis with a second known patho-
genic mutation, e.g. MYH7 Val606Met and Ala728Val in
hypertrophic cardiomyopathy (Blair et al. 2001). Similarly,
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two missense mutations in cis, each individually exerting a
comparatively mild or no effect on the clinical phenotype,
can act in concert leading to a more severe effect on the
phenotype than either acting alone (e.g. CFTR Arg347His
and Asp979Ala in cystic fibrosis; Clain et al. 2001 or RET
Cys634Tyr and Tyr791Phe resulting in pheochromocytoma
with high penetrance; Toledo et al. 2010). By contrast,
Brugnoni et al. (2013) have intriguingly claimed that two
different CLCN1 mutations do not give rise to myotonia
congenita when they occur in cis on the same allele,
although both lesions cause the disease when inherited on
their own.
In diseases that exhibit locus heterogeneity, clinical
penetrance may vary between mutations in different genes.
For example, in pancreatitis, penetrance may vary from
virtually 100 % in the case of the most common mutations
in the cationic trypsinogen gene (PRSS1) gene, via an
intermediate level for SPINK1 and CFTR mutations, to the
much more subtle risk conferred by the disease modifiers,
namely variants in the chymotrypsin C (CTRC), calcium-
sensing receptor (CASR) and anionic trypsin (PRSS2)
genes, which can only be identified through large cohort
studies (Lerch et al. 2010). It should, however, be noted
that in cases where mutations in the SPINK1 and CASR
genes (Felderbauer et al. 2003) or SPINK1 and CFTR genes
(Masson et al. 2007) are co-inherited, chronic pancreatitis
can ensue. Other such examples of digenic inheritance are
discussed below (see digenic mutations and disease
penetrance).
Reduced penetrance alleles are also characteristic of
many triplet repeat expansion disorders. For example, in
Huntington disease, the possession of intragenic (HTT)
CAG repeats of 36–39 copies (in 0.01 % of controls and
*5 % of consultands) is often associated with reduced
penetrance manifesting as a later onset of clinical symp-
toms (McNeil et al. 1997; Quarrell et al. 2007; Sequeiros
et al. 2010; Panegyres and Goh 2011; Huntington Study
Group COHORT Investigators 2012). Contractions of the
expanded CAG repeat length below a certain threshold can
occasionally be responsible even for the non-occurrence of
Huntington disease in a given at-risk individual (Nahhas
et al. 2009). However, it should be appreciated that a
substantial proportion of the variance in age of onset in
Huntington disease is due either to variation in genes other
than HTT or in the environment (Wexler et al. 2004). Other
repeat expansion disorders characterized by reduced pen-
etrance of alleles of intermediate size include fragile
X-associated tremor/ataxia syndrome (Jacquemont et al.
2004; Se´vin et al. 2009), spinocerebellar ataxia types 10
(Alonso et al. 2006; Rankin et al. 2008) and 17 (Oda et al.
2004; Nolte et al. 2010), inherited prion disease (Kaski
et al. 2011) and amyotrophic lateral sclerosis (Boeve et al.
2012; Ogaki et al. 2012).
Modulating influence of additional allelic variants
in cis or in trans
Some allelic variants may influence the expression of their
host gene so as to alter the penetrance of a potentially
pathological mutation in the same gene. Such modulatory
variants may reside within exons, introns or regulatory
regions. For example, the common Arg413Gln F7 poly-
morphism (Arg353Gln in legacy nomenclature; rs6046),
which serves to reduce the level of secreted coagulation
factor VII by *25 % (Arbini et al. 1994; Hunault et al.
1997), is over-represented among individuals with clini-
cally symptomatic factor VII deficiency (Millar et al.
2000). This is consistent with the view that Arg413Gln is a
functional polymorphism and that the presence of Gln413
increases the likelihood that an individual, whose haemo-
static potential is already compromised by a heterozygous
F7 mutation, will come to clinical attention due to a
bleeding diathesis. The same principle applies to the
functional Arg202Gln MEFV polymorphism (rs224222)
where the Gln202 allele occurs in the homozygous state at
a disproportionately higher frequency (15 %) in familial
Mediterranean fever patients than in normal controls
(2.7 %) (Yigit et al. 2012). In similar vein, the T allele of a
functional C/T polymorphism (rs11024595) in the pro-
moter region of the SAA1 gene is significantly over-rep-
resented in familial Mediterranean fever patients as
compared with normal controls (Migita et al. 2013). The
MLH1 Lys618Ala mutation (AAG[GCG; rs35502531),
initially supposed to be a benign polymorphism, has been
found to be significantly over-represented in sporadic
cancers associated with Lynch syndrome; MLH1 Ala618
appears to have a reduced ability to bind PMS2, one of the
MLH1 protein’s mismatch repair partners (Medeiros et al.
2012). Finally, the functional KCNE1 Asp85Asn poly-
morphism (rs1805128), which occurs in the general pop-
ulation with a frequency of 0.8 %, occurs at a frequency of
3.9 % in long QT syndrome patients (Nishio et al. 2009).
Various reported examples of the modulation of the
impact of pathogenic missense mutations by allelic single
nucleotide polymorphisms (SNPs) are given in Table 2.
Thus, the missense polymorphism Asp216His (rs1801968)
in the TOR1A (DYT1) gene serves to moderate the clinical
impact, in both cis and in trans, of the TOR1A c.904-906
del GAG mutation, the major mutation underlying early-
onset dystonia (Kock et al. 2006; Risch et al. 2007; Martino
et al. 2013). Similarly, in long QT syndrome, the genotype
of a missense polymorphism (Lys897Thr; rs1805123) in
the KCNH2 gene appears to distinguish symptomatic from
asymptomatic individuals carrying a low-penetrance
Ala1116Val pathogenic mutation (Crotti et al. 2005).
Another example of the modulatory effect of a missense
polymorphism on disease allele penetrance is provided by
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the His558Arg substitution (rs1805124) in the SCN5A gene
in a case of Brugada syndrome type 1 caused by compound
heterozygous mutations (Asp1690Asn and Gly1748Asp) in
SCN5A. Both mutations reduced the peak Na? current
density due to limited trafficking of the SCN5A protein
towards the membrane, but Gly1748Asp also profoundly
Table 2 Examples of pathogenic microlesions whose penetrance has been found to be modulated by allelic SNPs
Disease Gene Pathological mutation Modifying SNP Reference
Factor VII deficiency F7 Various NM_000131.3: c.1238G[A Arg413Gln
(rs6046)
Millar et al. (2000)
Brugada syndrome SCN5A NM_198056.2: c.5243G[A Gly1748Asp NM_198056.2: c.1673A[G His558Arg
(rs1805124)
Nu´n˜ez et al. (2013)
Familial sick sinus syndrome SCN5A Various NM_198056.2: c.1673A[G His558Arg
(rs1805124)
Gui et al. (2010)
Early-onset dystonia TOR1A NM_000113.2: c.907-909delGAG NM_000113.2: c.646G[C Asp216His
(rs1801968)
Kock et al. (2006) and
Risch et al. (2007)
Familial Mediterranean fever MEFV Various NM_000243.2: c.605G[A Arg202Gln
(rs224222)
Yigit et al. (2012)
Lynch syndrome MLH1 Various NM_000249.3:
c.1852_1853delAAinsGC Lys618Ala
(rs35502531)
Medeiros et al. (2012)
Long QT syndrome KCNH2 NM_000238.3: c.3347C[T Ala1116Val NM_000238.3: c.2690A[C Lys897Thr
(rs1805123)
Crotti et al. (2005)
Long QT syndrome KCNH2 NM_000238.3: c.1468G[A Ala490Thr NM_000238.3: c.2690A[C Lys897Thr
(rs1805123)
Zhang et al. (2008)
Creutzfeld–Jakob disease/
fatal familial insomnia
PRNP NM_000311.3: c.532G[A Asp178Asn NM_000311.3: c.385A[G Met129Val
(rs1799990)
Goldfarb et al. (1992) and
Apetri et al. (2005)
Cardiac conduction
abnormalities/sudden death
SCN5A NM_198056.2: c.4262G[A
Trp1421Term
NM_198056.2: c.3578G[A Arg1193Gln
(rs41261344)
Niu et al. (2006)
Sudden unexplained death SCN5A NM_198056.2: c.2039G[A Arg680His NM_198056.2: c.3308C[A Ser1103Tyr
(rs7626962)
Cheng et al. (2011)
Syncope SCN5A NM_198056.2: c.5851G[T Val1951Leu NM_198056.2: c.1673A[G His558Arg
(rs1805124)
Shinlapawittayatorn et al.
(2011)
Medullary thyroid carcinoma RET NM_020975.4: c.1996A[G Lys666Glu NM_020975.4: c.2071G[A Gly691Ser
(rs1799939)
Borrello et al. (2011)
Medullary thyroid carcinoma RET NM_020975.4: c.1597G[T Gly533Cys NM_020975.4: c.74-126G[T
(rs2565206)
Tamanaha et al. (2009)
Homocystinuria MTRR NM_002454.2: c.166G[A Val56Met NM_002454.2: c.66G[A Ile22Met
(rs1801394)
Gherasim et al. (2007)
Childhood absence epilepsy CACNA1H NM_021098.2: c.2318G[A Gly773Asp NM_021098.2: c.2362C[T Arg788Cys
(rs3751664)
Vitko et al. (2005)
Primary hyperoxaluria type 1 AGXT NM_000030.2: c.731T[C Ile244Thr NM_000030.2: c.32C[T Pro11Leu
(rs34116584)
Santana et al. (2003)
Hereditary spherocytosis SPTA1 NM_003126.2: c.7134G[A Gln2377Gln,
alters splicing of exon 51
c.4339-99C[T (rs200830867) Delaunay et al. (2004)
Erythropoietic
protoporphyria
FECH Various NM_000140.3: c.315-48T[C
(rs2272783)
Gouya et al. (2006)
Autosomal dominant
osteopetrosis type II
CLCN7 Various NM_001287.4: c.1252G[A Val418Met
(rs12926089)
Chu et al. (2005)
Haemolytic uraemic
syndrome
CFH Various NM_000186.3: c.2808G[T Glu936Asp
(rs1065489)
Caprioli et al. (2003)
Hereditary spastic paraplegia SPAST NM_014946.3: c.1687G[A, (alters
splicing of exon 15)
NM_014946.3: c.131C[T Ser44Leu
(rs121908515)
Pantakani et al. (2008)
GM1 gangliosidosis GLB1 NM_000404.2: c.601C[T Arg201Cys NM_000404.2: c.1306C[T Leu436Phe
(rs34421970)
Caciotti et al. (2003)
Primary cortisol resistance NR3C1 NM_001018077.1: c.2035G[A
Gly679Ser
NM_001018077.1: c.68G[A Arg23Lys
(rs6190)
Raef et al. (2008)
Atopic dermatitis SPINK5 NM_006846.3: c.2468dupA NM_006846.3: c.1258G[A Glu420Lys
(rs2303067)
Di et al. (2009)
Hyperinsulinism HADH NM_005327.4: c.636?471G[T NM_005327.4: c.636?385A[G
(rs732941)
Flanagan et al. (2013)
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affected channel gating. The His558Arg polymorphism
was found to be capable of rescuing the defective traf-
ficking of SCN5A Asn1690 towards the membrane when
present in cis to the pathological lesion (Nu´n˜ez et al. 2013).
Intriguingly, cotransfection with Asn1690, either alone or
together with the modulatory His558Arg polymorphism,
completely restored the gating defect associated with the
pathogenic Gly1748Asp mutation in trans, although it only
slightly rescued its trafficking.
In passing, it is perhaps pertinent to note that interplay
between functional SNPs may, depending upon the precise
combination of alleles involved, also be sufficient to bring
about disease in the absence of a pathogenic mutation sensu
stricto. Thus, a particular allele of one SNP may contribute to
pathogenesis, but only in the presence of specific allele of
another SNP. These SNPs may be neighbouring, as in the case
of Glu918Asp (rs16022) and Glu993Val (rs16023) in the
CACNA1A gene, which appear to contribute to migraine
susceptibility (D’Onofrio et al. 2009). In the same way, when
they occur together in cis, two otherwise neutral missense
polymorphisms in the FMO3 gene [Glu158Lys (rs2266782)
and Glu308Gly (rs2266780)] result in a decrease in FMO3
enzymatic activity that is sufficient to give rise to a mild form
of trimethylaminuria (Akerman et al. 1999; Zschocke et al.
1999; D’Angelo et al. 2013). However, the interacting SNPs
can also be located within different genes as in the case of
Pro589Ser (rs1049296) in the transferrin (TF) gene and
Cys282Tyr (rs1800562) in the haemochromatosis (HFE) gene
which interact so as to increase the risk of Alzheimer disease
(Robson et al. 2004; Kauwe et al. 2010). A further example of
the combined effect of two unlinked SNPs is provided by an
intronic SNP in the thrombospondin 2 (THBS2) gene (c.1478-
8C[T; rs 9406328) and a missense SNP in the metallopro-
teinase 9 (MMP9) gene (Gln279Arg; rs17576), which toge-
ther increase the risk of lumbar disc herniation (Hirose et al.
2008). This type of situation may occupy the middle ground
between monogenic and complex disorders.
The modifying SNP may also be regulatory in nature
and can serve to render the pathogenic coding mutation
more or less deleterious (and hence more or less penetrant)
depending upon whether the allele harbouring it is more or
less expressed than the wild-type allele. An example of this
is provided by the -30C[T variant (rs17249141) in the
LDLR gene promoter that has been shown to act in concert
with a low-penetrant missense mutation in cis so as to give
rise to an unusually severe form of familial hypercho-
lesterolaemia (Snozek et al. 2009). The modulating influ-
ence of regulatory SNPs on the penetrance of coding
mutations located in cis appears to be a widespread phe-
nomenon in medical genetics, with the high expressing
SNP allele usually increasing the clinical penetrance of the
linked coding mutation (Lappalainen et al. 2011). One
regulatory SNP is thought to act as a low-penetrance cancer
susceptibility factor in its own right: homozygosity for the
intronic 309T[G MDM2 variant (rs2279744), which leads
to enhanced binding of the Sp1 transcription factor and
MDM2 up-regulation, appears to increase the risk for many
types of tumour, presumably in concert with other lesions
(Hu et al. 2007).
Introns may also harbour SNPs that are capable of
modulating the clinical penetrance of a given pathogenic
mutation. Thus, a short tract of five thymidines (5T) in
intron 8 of the CFTR gene, found in *10 % of individuals
from the general population, can give rise to either con-
genital absence of the vas deferens (CAVD), non-classical
cystic fibrosis or a normal phenotype when found in trans
to a severe CFTR mutation (Kiesewetter et al. 1993;
Cuppens et al. 1998). The number of TG repeats immedi-
ately adjacent to 5T is not only significantly associated
with the level of alternative splicing of exon 9 of the CFTR
gene (Cuppens et al. 1998; Niksic et al. 1999), but also
influences clinical penetrance both in the context of cystic
fibrosis and CAVD (Groman et al. 2004; Buratti et al.
2004; Lebo and Grody 2007). Another intronic modifying
polymorphism is found in the FECH gene responsible for
erythropoietic protoporphyria, an autosomal dominant
disorder characterized by incomplete penetrance. This
polymorphism (c.315-48T[C; rs2272783) modulates the
use of a cryptic acceptor splice site, yielding an aberrantly
spliced FECH mRNA which is degraded via nonsense-
mediated mRNA decay (Gouya et al. 1999, 2002). The
hypomorphic C allele increases the penetrance of erythro-
poietic protoporphyria when it occurs in trans to a patho-
genic FECH mutation (Gouya et al. 2002, 2006). Finally,
in a family with hyperinsulinism, a c.636?385A[G SNP
(rs732941) in intron 5 of the HADH gene, which creates a
cryptic acceptor splice site, acts in concert with a patho-
genic HADH mutation (c.636?471G[T) in the same
intron, which creates a cryptic donor splice site, to generate
a 141-bp pseudoexon that leads to premature termination of
translation (Flanagan et al. 2013).
A common C[T variant within an enhancer in intron 1 of
the RET gene (rs2435357) serves to increase the clinical
penetrance of RET coding sequence mutations (Emison et al.
2005). The T allele disrupts a SOX10-binding site, thereby
reducing RET transactivation (Emison et al. 2010). A com-
parable example is provided by an intronic enhancer SNP
(rs2596623) in the thyroid hormone receptor b (THRB) gene,
which was found to be responsible for the pituitary cell-spe-
cific over-expression of a mutant thyroid hormone receptor b2
(Arg338Trp) in a case of pituitary cell-specific resistance to
thyroid hormone (Alberobello et al. 2011).
Variants in the 30 untranslated region (30UTR) of the
KCNQ1 gene reportedly modify disease severity in indi-
viduals with type 1 long QT syndrome resulting from
KCNQ1 gene mutations (Amin et al. 2012). These variants
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serve to reduce KCNQ1 gene expression, such that patients
with one or more variants on their mutated KCNQ1 alleles
have a shorter QT interval and a milder clinical phenotype,
whereas patients with the variants on their normal KCNQ1
alleles exhibit significantly longer QT intervals and a more
severe clinical phenotype. Another example of a modifying
30UTR variant is provided by the G[A polymorphism
(rs1799963) at position 20210 in the prothrombin (F2)
gene, which increases the risk of venous thrombosis by
enhancing F2 mRNA 30 end formation efficiency, thereby
boosting thrombin formation (Gehring et al. 2001). This F2
20210G[A polymorphism has been claimed to interact
with a common F13A1 Val34Leu (rs5985) variant to
confer a greatly increased risk of myocardial infarction
(Butt et al. 2003). Some 30UTR variants are located within
microRNA-binding sites and may constitute low-pene-
trance risk factors for disease in their own right (Ahluwalia
et al. 2009; Kontorovich et al. 2010; Qiu et al. 2011;
Arnold et al. 2012). Finally, various SNPs in other non-
coding RNAs (e.g. lincRNAs; Jendrzejewski et al. 2012;
Kumar et al. 2013) appear to be disease associated and may
therefore also influence disease penetrance.
Influence of the gene expression level on mutation
penetrance
Humans are characterized by marked inter-individual dif-
ferences in the expression levels of their genes (Stranger
et al. 2007; Skelly et al. 2009; Cowley et al. 2009; Cheng
et al. 2012). Since gene expression is controlled by a
combination of cis- and trans-acting regulatory factors, one
means by which heritable differences in gene expression
may be mediated is through polymorphism either of trans-
acting regulatory (transcription) factors or of the cis-acting
target sequences to which they bind. In the case of disease
genes, such inter-individual variation in gene expression
levels and patterns can influence the penetrance of patho-
logical mutations. However, it should be appreciated that
there are also substantial environmental and stochastic
(non-genetic) components to gene expression that are
likely to contribute to variable penetrance, even between
monozygotic twins (Grundberg et al. 2012).
Differential allelic expression is a widespread phenom-
enon and is thought to be relevant to as many as 50 % of all
human genes (Williams et al. 2007; Cheung and Spielman
2009; Palacios et al. 2009). In autosomal dominant condi-
tions where the two alleles of the disease gene are expressed
at different levels, this discrepancy can favour either the
mutant or the wild-type allele and hence may influence
clinical penetrance in either direction (de la Chapelle 2009).
Thus, in pulmonary arterial hypertension, a disease caused
by mutations in the bone morphogenetic protein receptor
type 2 (BMPR2) gene, the penetrance of the BMPR2 disease
allele is dependent upon the level of expression of the wild-
type BMPR2 allele (Hamid et al. 2009a). Similarly, in
erythropoietic protoporphyria, an autosomal dominant
condition caused by mutations in the ferrochelatase (FECH)
gene, the penetrance of the pathogenic FECH allele is
influenced by the level of expression of the wild-type FECH
allele (Gouya et al. 1999; 2002; Di Pierro et al. 2007). Other
examples of autosomal dominant conditions where the
degree of clinical penetrance is modulated by differential
expression of the wild-type and mutant alleles include
hereditary elliptocytosis (SPTA1, Wilmotte et al. 1993),
Marfan syndrome (FBN1, Hutchinson et al. 2003), retino-
blastoma (RB1, Taylor et al. 2007), colorectal cancer (APC,
Yan et al. 2002; TGFBR1, Valle et al. 2008) and breast and
ovarian cancer (BRCA1, Ginolhac et al. 2003).
Perhaps, the best understood example of penetrance
depending upon the level of expression of the wild-type
allele is retinitis pigmentosa type 11 (Utz et al. 2013). This
autosomal dominant condition is caused by mutations in
the pre-mRNA processing factor 31 (PRPF31) gene loca-
ted on chromosome 19q13.42. The clinical penetrance of
the underlying mutations has been shown to depend upon
the level of wild-type PRPF31 mRNA expression dis-
played by the patient (Vithana et al. 2003; Rivolta et al.
2006; Liu et al. 2008). Cells from asymptomatic carriers of
PRPF31 mutations express a higher level of the wild-type
allele than cells from affected patients: high enough for the
wild-type PRPF31 mRNA level to lie within the range of
the unaffected general population (Rivolta et al. 2006; Liu
et al. 2008). The penetrance of PRPF31 mutations is
reduced by transcriptional repression mediated by the
product of the CCR4-NOT transcription complex, subunit
3 (CNOT3) gene which is linked to PRPF31 (McGee et al.
1997; Venturini et al. 2012). PRPF31 expression has also
been found to be strongly influenced by an unlinked eQTL
on chromosome 14q21-q23 (Rio Frio et al. 2008). The
penetrance of PRPF31 mutations is therefore determined at
least in part by a trans-acting modifier located on a dif-
ferent chromosome. The trans-acting alleles are inherited
from the parent lacking the PRPF31 mutation; these alleles
are presumably present in the general population, but
appear only to be relevant to disease when they modulate
the penetrance of PRPF31 mutations.
A slightly different scenario is exemplified by Schimke
immune-osseus dysplasia (SIOD), a recessive condition,
which appears to result from biallelic mutations in the
SMARCAL1 gene. Several examples of SIOD families with
incomplete penetrance have been reported (Bo¨kenkamp
et al. 2005; Dekel et al. 2008; Elizondo et al. 2009). It has
recently been shown that SMARCAL1, a protein involved
in chromatin remodelling, influences the transcription level
of many genes (Baradaran-Heravi et al. 2012). Although
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SMARCAL1 deficiency is insufficient in itself to cause
SIOD in Drosophila and mouse models, the addition of
environmental (viz. heat shock) and genetic insults
affecting transcription can successfully recapitulate the
pathophysiology of SIOD (Baradaran-Heravi et al. 2012).
The penetrance of SIOD therefore appears to be dependent
upon the magnitude of the alteration of gene expression
consequent to SMARCAL1 deficiency.
In the case of a splicing mutation (c.291?1 G[A;
rs71640277) in intron 3 of the GH1 gene causing growth
hormone deficiency type II, the expression levels of the
mutant and wild-type alleles were found to correlate with
the penetrance and expressivity of the deficiency state in
different members of the same family (Hamid et al. 2009b).
Some splicing mutations associated with low penetrance
affect splicing in such a way that both normal-length and
truncated transcripts are expressed from the same mutant
allele, but presumably to different extents in different
individuals (e.g. RB1, c.2211G[A; Schubert et al. 1997).
Other such examples of reduced penetrance due to ‘leaky
splicing’ involve splicing mutations in the SPAST gene
causing hereditary spastic paraplegia (Svenson et al. 2001)
and in the BTK gene causing X-linked agammaglobulina-
emia (Kaneko et al. 2005). The reduced penetrance char-
acteristic of some splicing mutations may also result from
alternative splicing (Rave-Harel et al. 1997; Chiba-Falek
et al. 1998; Nissim-Rafinia and Kerem 2005; Zinman et al.
2009; Szymanski et al. 2011; Cogan et al. 2012; Lee et al.
2012b) or internal translational start site initiation (Sa´n-
chez-Sa´nchez et al. 2007).
Special cases of differential allelic expression are of
course provided by X-inactivation (Dobyns et al. 2004) and
imprinting (Lo et al. 2003), both of which are discussed
below.
Allele dosage and its influence on penetrance
Formally, use of the term ‘autosomal dominant’ implies
that the homozygotes exhibit the same or a similar clinical
phenotype to the heterozygotes, as is the case in Hun-
tington disease where the length of the expanded HTT
CAG triplet repeat appears to be predictive of the age of
onset irrespective of the presence or absence of a second
expanded HTT allele (Lee et al. 2012a). However, in
practice, for most ‘dominant’ human disorders in which
homozygotes have been reported, their clinical symptoms
tend to be significantly more severe than in the heterozy-
gotes (Vogel and Motulsky 1997). This would seem to be
especially true in the context of low-penetrance mutations
such as those identified in the SCN4A and CLCN1 genes,
causing muscle channelopathies, conditions which are
usually held to be transmitted in an autosomal dominant
fashion. Patients homozygous for sodium channel mutations
causing paramyotonia congenita (SCN4A, Ile1393Thr),
hypokalemic periodic paralysis (SCN4A, Arg1132Gln) and
myotonia congenita (CLCN1, Gly190Ser, Ile556Asn,
Ala313Thr, Ile556Asn) display much more severe clinical
features than patients heterozygous for these mutations
(Plassart-Schiess et al. 1998; Arzel-He´zode et al. 2010; Sha-
lata et al. 2010). The aforementioned mutations were also
found to exhibit reduced penetrance in heterozygotes.
Mutations in the RET gene, associated with isolated Hir-
schsprung disease, are dominant loss-of-function mutations
with incomplete penetrance and variable expressivity. Basel-
Vanagaite et al. (2007) reported a c.1263?5G[A splicing
mutation in the homozygous state in three females with
severe Hirschsprung disease and in the heterozygous state in a
male patient with short-segment Hirschsprung disease. In
addition, a hypomorphic RET-predisposing allele, rs2435357,
located in the first intron of the RET gene, was found in the
heterozygous state in the male patient but not in the three
affected females. Whilst the heterozygous c.1263?5G[A
mutation is known to be low penetrance for short-segment
Hirschsprung disease, the homozygous state is fully penetrant
for total aganglionosis or long-segment Hirschsprung disease.
Thus, the penetrance of RET gene mutations in Hirschsprung
disease depends not only on the nature of the mutation but
also on the allele dosage.
Influence of copy number variation on mutation
penetrance
Estimates of the clinical penetrance of recurrent pathogenic
copy number variants (CNVs) vary quite widely, depending
upon CNV size, genomic location and the disorder in question
(Ben-Shachar et al. 2009; Vassos et al. 2010; Breckpot et al.
2011; Cˇiuladaite` et al. 2011; Hosak et al. 2012; Klopocki et al.
2012; Rosenfeld et al. 2013; Vaags et al. 2012; Weischenfeldt
et al. 2013; Dabell et al. 2013; Carvill and Mefford 2013;
Tropeano et al. 2013). In their study of children known to carry
a CNV associated with intellectual disability and congenital
abnormalities, Girirajan et al. (2012) reported synergy
between multiple large CNVs leading to a particularly severe
clinical presentation. Such a two-hit model, or ‘oligogenic
heterozygosity’ as it has been termed, also appears to be
characteristic of autism (Pinto et al. 2010; Schaaf et al. 2011b;
Klei et al. 2012; Gau et al. 2012).
The penetrance of a given CNV may also be influenced
by genetic variants in the vicinity. Thus, a submicroscopic
deletion of 1q21.1 (encompassing the RBM8A gene) has
been reported to interact with a low-frequency functional
SNP in the regulatory region of the wild-type RBM8A
allele to cause thrombocytopaenia with absent radii (Albers
et al. 2012).
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Several papers have now suggested that CNVs can also act
as genetic modifiers of phenotype severity in a variety of
different disease contexts (Beckmann et al. 2007; Chaudru
et al. 2009; El-Hattab et al. 2010; Mulley et al. 2011; Jiang
et al. 2011; Carvalho et al. 2012; Shen et al. 2013b). CNVs
may influence the penetrance of a clinical phenotype indi-
rectly as well as directly. For example, a mutant gene might
be ‘covered’ by a CNV in a given individual, so that the
expected clinical phenotype would be masked by the pres-
ence of an additional wild-type copy in cis to the gene in
question. Consistent with this postulate, Ng et al. (2008)
reported that *30 % of nonsense SNPs occur in genes
residing within segmental duplications, a proportion some
threefold larger than that noted for synonymous SNPs. Genes
harbouring nonsense SNPs were also found to belong to
larger gene families (Ng et al. 2008) suggesting that some
functional redundancy could also exist between paralogous
human genes. In support of this idea, Hsiao and Vitkup
(2008) reported that those human genes which have a
homologue with [90 % sequence similarity are *3 times
less likely to harbour disease-causing mutations than genes
with less closely related homologues. Hsiao and Vitkup
(2008) interpreted their findings in terms of ‘genetic
robustness’ against null mutations, with the duplicated
sequences providing ‘backup’ by potentiating the functional
compensation/complementation of homologous genes in the
event that the latter acquired deleterious mutations. The
capacity to be functionally compensated appears to vary, in
the order non-disease genes [ monogenic disease genes
[ polygenic disease genes (Podder and Ghosh 2011). One
example of how a CNV can ameliorate the clinical phenotype
is spinal muscular atrophy where an increased copy number
of the SMN2 gene can greatly reduce the severity of the
disease caused by the homozygous deletion of the SMN1
gene, because the SMN2 gene, which lacks a splicing
enhancer, can nevertheless generate some functional product
thereby compensating functionally in a copy number-
dependent fashion for the loss of the SMN1 gene (Vitali et al.
1999; Harada et al. 2002; Wirth et al. 2006). Another
example of how the clinical and/or phenotypic impact of a
mutant gene can be nullified by a CNV is provided by a
foetus that possessed paternal (Gln318Term) and maternal
(Arg356Term) nonsense mutations of the CYP21A2 gene but
lacked the normal clinical sequelae of congenital adrenal
hyperplasia; this was found to be due to a duplication of the
CYP21A2 gene on the paternal allele (Kleinle et al. 2009;
Lekarev et al. 2013).
Influence of modifier genes on disease penetrance
‘‘For a so-called single gene disorder, there is one
gene that may be primarily responsible for the
pathogenesis with one or more independently inher-
ited modifier genes that influence the phenotype. On
the other hand, for a complex trait, the primacy of any
individual gene is not perceptible, and the interaction
of two or more independently inherited pairs of
alleles, most likely influenced by additional modifier
genes, results in the disease. The consequence of this
conceptual framework is that there is no such thing as
a ‘single’ gene disorder. In other words, there is no
obvious clear distinction between simple Mendelian
and complex traits: genetic diseases represent a
continuum with diminishing influence from a single
primary gene influenced by modifier genes, to
increasingly shared influence by multiple genes’’.
Dipple and McCabe (2000)
It is sometimes claimed that sickle cell anaemia is the
simplest of all Mendelian disorders in that it is caused by
one specific mutation (Glu7Val) in the b-globin (HBB)
gene. However, this single-mutation monogenic disorder is
not as simple as it might at first appear; indeed, it is
characterized by marked clinical heterogeneity and
incomplete penetrance of subphenotypes which is due in
part to allelic variation and in part to variants in unlinked
modifier genes (Steinberg and Sebastiani 2012). If we
extrapolate from the archetypal example of sickle cell
disease to other Mendelian disorders, it is not unreasonable
to expect the action of modifier genes to be the rule rather
than the exception. Indeed, variants in unlinked modifier
genes have been reported to influence penetrance in a
variety of different inherited diseases including pancreatitis
(Khalid et al. 2006), breast cancer (Wolf et al. 2010; Wang
et al. 2010a; Walker et al. 2010; Antoniou and Chenevix-
Trench 2010; Esteban Carden˜osa et al. 2012; Harlid et al.
2012), Gaucher disease (Taddei et al. 2009; Zhang et al.
2012), retinitis pigmentosa (Rio Frio et al. 2008; Venturini
et al. 2012), haemochromatosis (Krayenbuehl et al. 2010),
hypertrophic cardiomyopathy (Daw et al. 2007), fronto-
temporal lobar degeneration (Finch et al. 2011) and amy-
loid polyneuropathy (Soares et al. 2005) among others. In
familial late-onset Alzheimer disease, modifying loci may
either influence the risk (Sleegers et al. 2009; Cruchaga
et al. 2012) or the age of onset of disease (Wijsman et al.
2005; Marchani et al. 2010). Importantly, a significant
excess of rare coding APP, PSEN1 and PSEN2 variants
was noted in probands from late-onset Alzheimer disease
families even though these variants did not actually co-
segregate with the disease; this suggests that the variants in
question may nevertheless serve to modulate the risk of
disease (Cruchaga et al. 2012). An excess of rare variants
as compared to controls has also been noted in patients
with various other disorders including hypertriglycerida-
emia (Johansen et al. 2012; Talmud 2007), hypertrophic
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cardiomyopathy (Lopes et al. 2013) and autism spectrum
disorder (Mondal et al. 2012).
A typical example of a modifier gene in action is pro-
vided by long QT syndrome. The clinical penetrance of
KCNQ1 (potassium voltage-gated channel, KQT-like sub-
family, member 1) mutations in this disorder is influenced
by two coding sequence polymorphisms [Ser49Gly
(rs1801252) and Arg389Gly (rs1801253)] in the ADRB1
gene. Individuals homozygous for the Arg389 allele tend to
have shorter QT intervals, whereas individuals homozy-
gous for Ser49 tend to have longer QT intervals than those
with other genotypes (Paavonen et al. 2007). Interestingly,
those individuals doubly homozygous for Arg389 and
Ser49 were found to be indistinguishable from the
remainder of the patient cohort, both in terms of their QT
intervals and in terms of clinical penetrance.
The minor allele of a variant in the complement receptor 1
(CR1) gene, Ser1610Thr (rs4844609), which has a population
frequency of 0.02, is associated with episodic memory decline
and susceptibility to Alzheimer disease (Keenan et al. 2012).
However, this effect appears largely dependent upon an
interaction with APOE-e4, itself an important risk factor for
Alzheimer disease (Mayeux et al. 1993).
Hirschsprung disease is one of the most complex genetic
disorders in terms of the number of modifier genes (Garcia-
Barcelo et al. 2009; Tang et al. 2010) known to influence
the penetrance of its causative mutations, which has been
estimated to be of the order of 50–70 % (Bolk et al. 2000).
The best characterized of these modifier genes is the neu-
regulin 1 gene (NRG1; Tang et al. 2011, 2012a); however,
most probably still remain to be identified. Some Bardet–
Biedl syndrome patients also present with Hirschsprung
disease. It appears that RET, the major gene involved in the
aetiology of Hirschsprung disease, acts as a modifier of the
Hirschsprung disease phenotype in Bardet–Biedl syndrome
(de Pontual et al. 2007). Some families with Hirschsprung
disease and Bardet–Biedl syndrome harbour mutations in
their BBS4, BBS5, BBS7 and RET genes (de Pontual et al.
2009). Sa´nchez-Mejı´as et al. (2009) reported a Hirsch-
sprung disease family in which mutations in three different
genes (RET, NTRK3 and EDN3) contributed to the disease
phenotype; the RET and NTRK3 mutations were both
necessary and sufficient to give rise to the clinical pheno-
type, whereas the EDN3 mutation appeared to act as a
modifier. More recently, copy number variations in various
neurodevelopmental genes (MAPK10, ZFHX1B, SOX2 and
NRG2) have been shown to modify the penetrance of
Hirschsprung disease (Jiang et al. 2011; Tang et al. 2012b).
Taken together, these findings are consistent with an
impact of both common and rare variants on the inheritance
(and hence penetrance) of this highly complex disorder
(Sa´nchez-Mejı´as et al. 2009; Nu´n˜ez-Torres et al. 2011;
Alves et al. 2013).
Table 3 lists a number of well-characterized examples
of specific variants in modifier genes that serve to modulate
the clinical penetrance of diseases caused by mutation(s) at
unlinked loci.
The plastin 3 (PLS3) gene acts as a modifier of the
clinical penetrance of autosomal recessive spinal muscular
atrophy, caused by the homozygous deletion of the SMN1
gene. Oprea et al. (2008) studied spinal muscular atrophy-
discordant families with affected and unaffected SMN1-
deleted siblings and found that all unaffected SMN1-
deleted siblings were characterized by a high PLS3
expression level in blood cells, considerably higher than in
their affected counterparts (and despite high PLS expres-
sion being evident in only 5 % of healthy controls).
Although it is still unclear whether PLS3 expression is
regulated by cis- or trans-acting factors, it would appear
that high PLS3 expression serves to rescue the spinal
muscular atrophy patient from the detrimental effects of
SMN1 deletion by promoting axonogenesis through ele-
vation of the level of F-actin (Oprea et al. 2008) and ulti-
mately by improving neuromuscular transmission
(Ackermann et al. 2013).
A unique kind of modifying effect is exemplified by a-
thalassaemia/mental retardation syndrome, caused by
mutations of the ATRX gene. The ATRX protein binds to
variable number tandem repeat sequences (VNTRs) in the
human genome, and genes associated with these VNTRs
are dysregulated when ATRX is mutated (Law et al. 2010).
Law et al. (2010) identified 917 ATRX targets in primary
human erythroid cells, including one in the a-globin (HBA)
locus. This wd VNTR was found to be highly polymorphic
in terms of its length and acted as a length-dependent
negative regulator of gene expression, its length serving to
influence the degree of a-thalassaemia observed in an a-
thalassaemia/mental retardation syndrome patient. Thus,
the length of the wd VNTR could explain the incomplete
penetrance of a-thalassaemia noted in individuals with
identical ATRX mutations. A similar mechanism could
underlie other genetic traits characterized by reduced
penetrance.
Digenic mutations and disease penetrance
In a typical autosomal Mendelian condition, a single
mutation (dominant) or two mutations (recessive) at a
specific locus give rise to a clinical phenotype. By contrast,
digenic inheritance occurs in cases where the interaction of
mutations in two different genes is required for the
expression of the clinical phenotype. In this situation, a
mutation in one copy of each gene is required for the full
clinical phenotype to manifest. In the absence of one of the
component mutations, the other mutation may be non-
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Table 3 A selection of well-characterized examples of polymorphic variants in modifier genes that serve to modulate the clinical penetrance
and/or severity of an inherited disease caused by mutation(s) at an unlinked locus
Disease Primary disease gene Modifier gene/variant Reference
X-linked retinitis
pigmentosa
RPGR IQCB1/NM_001023570.2:c.1178T[A Ile393Asn
(rs1141528)
Fahim et al. (2011)
X-linked retinitis
pigmentosa
RPGR RPGRIP1L/NM_015272.2:c.2231G[A Arg744Gln
(rs2302677)
Fahim et al. (2011)
Retinal generation in
ciliopathies
RPGR or NPHP5 RPGRIP1L/NM_015272.2:c.685G[A Ala229Thr
(rs61747071)
Khanna et al. (2009)
Retinoblastoma RB1 MDM2/NM_002392.4:c.14?309T[G (rs2279744) Caste´ra et al. (2010)
Familial
hypercholesterolaemia
LDLR PCSK9/NM_174936.3:c.63_65dupGCT (rs35574083) Abifadel et al. (2009)
Familial
hypercholesterolaemia
LDLR APOB/NM_000384.2:c.10580G[A Arg3527Gln
(rs5742904)
Benlian et al. (1996)
and Taylor et al. (2010)
Familial
hypercholesterolaemia
LDLR CFH/NM_000186.3:c.1204T[C Tyr402His (rs1061170) Koeijvoets et al. (2009)
Familial
hypercholesterolaemia
LDLR APOH/NM_000042.2:c.1204T[C Leu266Val (rs4581) Takada et al. (2003a)
Familial
hypercholesterolaemia
LDLR GHR/NM_000163.4:c.1630A[C Ile544Leu (rs6180) Takada et al. (2003b)
Familial
hypercholesterolaemia
LDLR EPHX2/NM_001979.4:c.860G[A Arg287Gln (rs751141) Sato et al. (2004)
Breast cancer BRCA2 RAD51/NM_002875.4:c.-98G[C (rs1801320) Antoniou et al. (2007)
Ovarian cancer BRCA1 or BRCA2 IRS1/NM_005544.2:c.2911G[A Gly971Arg (rs801278) Ding et al. (2012)
Lynch syndrome MSH2 or MLH1 RNASEL/NM_021133.3:c.1385G[A Arg462Gln
(rs486907)
Kru¨ger et al. (2007)
Prostate cancer MSH2 or MLH1 RNASEL/NM_021133.3:c.1385G[A Arg462Gln
(rs486907)
Kru¨ger et al. (2005)
Lynch syndrome MSH2 or MLH1 TP53/NM_000546.3:c.215G[C Arg72Pro (rs1042522) Kru¨ger et al. (2007)
Cystic fibrosis CFTR TGFB1/NM_000660.4:c.29C[T Pro10Leu (rs1800470) Drumm et al. (2005)
Familial pulmonary
arterial hypertension
BMPR2 TGFB1/NM_000660.4:c.-1347C[T (rs1800469) &
NM_000660.4:c.29C[T Leu10Pro (rs1800470)
Phillips et al. (2008)
Paget’s disease SQSTM1 TNFRSF11A/NM_003839.2:c.575T[C Val192Ala
(rs1805034)
Gianfrancesco et al. (2012)
X-linked variable
immunodeficiency
XIAP CD40LG/NM_000074.2:c.655G[A Gly219Arg
(rs148594123)
Rigaud et al. (2011)
Haemochromatosis HFE CYBRD1/NM_024843.3:c.-399T[G (rs884409) Constantine et al. (2009)
Parkinson’s disease GBA MTX1/NM_002455.3:c.187T[A Ser63Thr (rs760077) Gan-Or et al. (2011)
Recessive dystrophic
epidermolysis bullosa
COL7A1 MMP1/NM_002421.3:c.-1673delG (rs1799750) Titeux et al. (2008)
Amyotrophic lateral
sclerosis
SOD1 CHGB/NM_001819.2:c.1238C[T Pro413Leu (rs742710) Gros-Louis et al. (2009)
Huntington disease HTT HAP1/NM_177977.2:c.1322C[T Thr441Met (rs4523977) Metzger et al. (2008)
Fatal kernicterus G6PD UGT1A1/(TA)6/(TA)7 (rs8175347), HGVS nomenclature
not available
Zangen et al. (2009)
Atypical haemolytic
uraemic syndrome
MCP or CFH C4BPA/NM_000715.3:c.719G[A Arg240His
(rs45574833)
Blom et al. (2008)
Spinal muscular atrophy SMN1 SMN2/NM_017411.3:c.859G[C Gly287Arg
(rs121909192)
Prior et al. (2009)
Long QT syndrome KCNQ1 KCNH2/NM_000238.3:c.2690A[C Lys897Thr
(rs1805123)
Cordeiro et al. (2010)
Long QT syndrome KCNQ1 ADRB1/NM_000684.2:c.145A[G Ser49Gly (rs1801252) &
NM_000684.2:c.1165G[C Arg389Gly (rs1801253)
Paavonen et al. (2007)
Long QT syndrome KCNQ1 NOS1AP/NC_000001.10:g.162029907A[T (rs4657139) Crotti et al. (2009)
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penetrant (digenic inheritance sensu stricto) or could be
responsible for a less severe clinical phenotype (digenic
inheritance sensu lato). At least 100 cases of probable and
possible examples of digenic inheritance causing human
inherited disease have been reported to date (Table 4).
Digenic inheritance may occur as a result of mutations
in genes encoding different subunits of the same multi-
meric protein (e.g. PRPH2 and ROM1), an oligomeric
protein complex (e.g. KCNJ10 and SLC26A4; KRT14 and
KRT5) or simply two proteins that interact functionally
with each other (CDH23 and PCDH15; DSG2 and DSC2;
PARK7 and PINK1). However, mutations in receptor/
ligand pairs can also give rise to digenic inheritance (e.g.
PROK2 and PROKR2). Alternatively, digenic inheritance
can involve mutations located in different genes, but
compromising the same regulatory (e.g. HFE and HAMP),
biosynthetic (e.g. ZMPSTE24 and LMNA; CPOX and
PPOX; MYOC and CYP1B1) or degradative (e.g. PCSK9
and LDLR) pathway. Finally, the combination of a mutation in
a transcription factor with a mutation in a target gene of that
transcription factor can also serve to reduce the amount of the
protein in question to a level sufficient to cause a disease
phenotype (e.g. MITF and TYR; FOXC1 and PITX2).
In practice, it is not always clear if a given situation
constitutes true digenic inheritance (e.g. Kajiwara et al.
1994) or whether it is simply the coinheritance of two
mutations in different genes (e.g. Gruber et al. 2009; Ser-
rano-Ferna´ndez et al. 2009; Ekvall et al. 2011). In the
former case, the expression of the disease phenotype
actually requires the presence of both gene lesions. In the
latter case, coinheritance of the two gene lesions may serve
to aggravate the clinical phenotype, but each lesion is
independently associated with its own characteristic clini-
cal sequelae. In true digenic inheritance, mutations in both
genes must be present for the genetic disorder to be man-
ifest. Since many of the disorders reported (in Table 4) to
be characterized by digenic inheritance also have mono-
genic forms in which just one of the two genes has been
mutated (whether in the heterozygous or homozygous/
compound heterozygous state), it is unclear how many of
the examples listed really represent digenic inheritance
sensu stricto. However, in many of the listed examples, the
doubly heterozygous probands exhibit earlier onset or a
more severe clinical phenotype than their singly hetero-
zygous relatives (although this is not invariably so; Marras
et al. 2010). Further, whereas the truly ‘digenic’ patients
tend to be characterized by complete penetrance, the
monogenic disease genotypes often exhibit reduced pene-
trance as in e.g. normosmic idiopathic hypogonadotrophic
hypogonadism (see Table 4).
In some of the cases listed in Table 4, the digenic
inheritance may be confined to a single proband and hence
it is not always straightforward to distinguish true digenic
inheritance from the chance coinheritance of two mutations
in unlinked genes. This notwithstanding, the requirement
for the involvement of a second mutated gene may depend
upon the specific mutations that are segregating in the
pedigrees. If digenic inheritance eventually turns out to be
more frequent than previously appreciated, it could provide
yet another reason why some potentially pathogenic alleles
are present in the general population in the absence of overt
disease. At the very least, in many cases the clinical pen-
etrance of the condition in question is likely to be greater
when two relevant genes have been functionally compro-
mised by mutation than if only one had been mutated.
Oligogenic inheritance and its implications for disease
penetrance
Triallelic inheritance has been described as being ‘‘a bridge
between Mendelian and multifactorial traits’’ (Eichers et al.
2004). There are a burgeoning number of reported exam-
ples of digenic triallelic inheritance including nephron-
ophthisis (Hoefele et al. 2007), venous thrombosis
(Formstone et al. 1996; Brenner et al. 1996) and cortisone
Table 3 continued
Disease Primary disease gene Modifier gene/variant Reference
Familial venous
thrombosis
PROC F5/NM_000130.4:c.1601G[A Arg534Gln (rs6025;
Factor V Leiden)
Koeleman et al. (1994);
Gandrille et al. (1995)
and Cafolla et al. (2012)
Familial venous
thrombosis
PROS1 F5/NM_000130.4:c.1601G[A Arg534Gln (rs6025;
Factor V Leiden)
Koeleman et al. (1995)
Familial venous
thrombosis
SERPINC1 F5/NM_000130.4:c.1601G[A Arg534Gln (rs6025;
Factor V Leiden)
Van Boven et al. (1996)
Hypertrophic
cardiomyopathy
MYBPC3 or MYH7 CALM3/NM_005184.2:c.-157T[A (rs150954567) Friedrich et al. (2009)
Familial Mediterranean
fever
MEFV SAA1/NM_000331.4:c.-197C[T (rs11024595) Migita et al. (2013)
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Table 4 Examples of digenic mutations causing human inherited disease
Disease Gene 1 Gene 2 Reference
Waardenburg syndrome type 2* MITF PAX3 or OCA3 or TYR or
GJB2
Morell et al. (1997); Chiang et al. (2009); Yan
et al. (2011) and Yang et al. (2013)
Retinitis pigmentosa* PRPH2 ROM1 or RHO or PDE6B Kajiwara et al. (1994); Loewen et al. (2001);
Sullivan et al. (2006) and Jin et al. (2008)
Retinitis pigmentosa RHO PRPF31 Lim et al. (2009)
Retinitis pigmentosa* PDE6B GPR98 Hmani-Aifa et al. (2009)
Progressive cone dystrophy CNGA3 CNGB3 Thiadens et al. (2010)
Frontotemporal dementia* PSEN1 PRNP Bernardi et al. (2011)
Leber congenital amaurosis* RPE65 GUCY2D Silva et al. (2004)
Idiopathic hypogonadotropic hypogonadism* FGFR1 GNRHR or NELF Pitteloud et al. (2007)
Bilateral cystic renal dysplasia DACH1 BMP4 Schild et al. (2013)
Glaucoma, early onset* MYOC CYP1B1 or LTBP2 Vincent et al. (2002), Geyer et al. (2011) and
Azmanov et al. (2011)
Severe insulin resistance PPARG PPP1R3A Savage et al. (2002)
Usher syndrome type 2* PDZD7 GPR98 Ebermann et al. (2010)
Usher syndrome type 1-associated deafness CDH23 PCDH15 Zheng et al. (2005)
Hidrotic ectodermal dysplasia GJB2 GJA1 Kellermayer et al. (2005)
Non-syndromic deafness* GJB2 GJB3 Liu et al. (2009)
Hearing loss GJB2 SLC26A4 Sagong et al. (2013)
Non-syndromic hearing loss associated with an
enlarged vestibular aqueduct/Pendred
syndrome
KCNJ10 SLC26A4 Yang et al. (2009)
Porphyria* CPOX PPOX van Tuyll van Serooskerken et al. (2011)
Atypical haemolytic uremic syndrome CFI CD46 or C3 or CFB or
CFHR1
Esparza-Gordillo et al. (2006), Westra et al.
(2010) and Bresin et al. (2013)
Atypical haemolytic uraemic syndrome CFH CD46 or CFI or C3 or
THBD
Sullivan et al. (2011), Bresin et al. (2013) and
Fan et al. (2013)
Epidermolysis bullosa simplex* KRT14 KRT5 Padalon-Brauch et al. (2012)
Junctional epidermolysis bullosa COL17A1 LAMB3 Floeth and Bruckner-Tuderman (1999)
Long QT syndrome* KCNQ1 KCNH2 or KCNE1 or
SCN5A
Schwartz et al. (2003), Westenskow et al. (2004),
Tester et al. (2005) and Itoh et al. (2010)
Long QT syndrome* KCNH2 SCN5A or KCNE1 Schwartz et al. (2003), Westenskow et al. (2004)
and Tester et al. (2005)
Long QT syndrome* SCN5A SNTA1 or KCNE1 Westenskow et al. (2004) and Hu et al. (2013)
Haemochromatosis* HFE HAMP or TFR2 Merryweather-Clarke et al. (2003), Jacolot et al.
(2004), Island et al. (2009), Alte`s et al. (2009)
and Del-Castillo-Rueda et al. (2012)
Kallmann syndrome* PROK2 PROKR2 Cole et al. (2008), Sarfati et al. (2010) and Shaw
et al. (2011)
Kallmann syndrome NELF KAL1 or TACR3 Xu et al. (2011) and Quaynor et al. (2011)
Kallmann syndrome PROKR2 KAL1 Dode´ et al. (2006), Canto et al. (2009) and Shaw
et al. (2011)
Kallmann syndrome KAL1 TACR3 or WDR11 or
CHD7
Quaynor et al. (2011) and Shaw et al. (2011)
Normosmic idiopathic hypogonadotrophic
hypogonadism
GNRH KAL1 Quaynor et al. (2011)
Normosmic idiopathic hypogonadotrophic
hypogonadism
WDR11 GNRHR Quaynor et al. (2011)
Normosmic idiopathic hypogonadotrophic
hypogonadism
FGFR1 GNRHR or PROKR2 or
FGF8 or KAL1 or GPR54
Raivio et al. (2009), Sykiotis et al. (2010) and
Shaw et al. (2011)
Systemic amyloid A amyloidosis TNFRSF1A MEFV Cigni et al. (2006) and Mereuta et al. (2013)
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Table 4 continued
Disease Gene 1 Gene 2 Reference
Familial hypercholesterolaemia* LDLR PCSK9 Pisciotta et al. (2006), Noguchi et al. (2010) and
Bertolini et al. (2013)
Familial hypercholesterolaemia LDLR APOB Bertolini et al. (2013)
Familial hypercholesterolaemia LDLR LDLRAP1 Tada et al. (2011)
Severe congenital neutropenia ELANE G6PC3 or HAX1 Germeshausen et al. (2010)
McArdle’s disease* PYGM CPT2 Vockley et al. (2000)
Parkinson’s disease, early onset PINK1 PARK2 or PARK7 Tang et al. (2006) and Funayama et al. (2008)
Parkinson’s disease LRRK2 PRKN Da¨chsel et al. (2006)
Emery–Dreifuss muscular dystrophy* LMNA DES Muntoni et al. (2006)
Joubert syndrome and nephronophthisis* NPHP1 NPHP6 Tory et al. (2007)
Axenfeld–Rieger syndrome FOXC1 PITX2 Kelberman et al. (2011)
Cortisone reductase deficiency HSD11B1 H6PD Draper et al. (2003) and San Milla´n et al. (2005)
Hypertrophic cardiomyopathy* MYBPC3 TNNT2 or TNNI3 or MYH7
or TPM1
Richard et al. (2003), Van Driest et al. (2004)
Ingles et al. (2005), Millat et al. (2010), Kubo
et al. (2011) and Zou et al. (2013)
Hypertrophic cardiomyopathy* MYH7 TNNT2 or MYL2 or TNNI3
or ACTC1
Millat et al. (2010) and Zou et al. (2013)
Restrictive cardiomyopathy* MYL2 MYL3 Caleshu et al. (2011)
Rasopathy phenotype with severe hypertrophic
cardiomyopathy
PTPN11 SOS1 Fahrner et al. (2012)
Arrhythmogenic right ventricular
cardiomyopathy
DES PKP2 Lorenzon et al. (2013)
Arrhythmogenic right ventricular
cardiomyopathy*
DES DSG2 Rasmussen et al. (2013)
Arrhythmogenic right ventricular
cardiomyopathy
PKP2 DSP or DSG2 or PKP4 or
DSC2
Xu et al. (2010)
Arrhythmogenic right ventricular dysplasia/
cardiomyopathy
DSG2 DSC or PKP2 Bhuiyan et al. (2009) and Nakajima et al. (2012)
Familial dilated cardiomyopathy* LMNA TTN Roncarati et al. (2013)
Dent’s disease CLCN5 OCRL Addis et al. (2013)
Amyotrophic lateral sclerosis SOD1 CNTF Giess et al. (2002)
Amyotrophic lateral sclerosis VAPB C9orf72 van Blitterswijk et al. (2012b)
Dravet syndrome PCDH19 TSPYL4 Kwong et al. (2012)
Dravet syndrome* SCN9A SCN1A Singh et al. (2009)
Dravet syndrome* CACNA1A SCN1A Ohmori et al. (2013)
Severe myoclonic epilepsy CACNB4 SCN1A Ohmori et al. (2008)
Severe myoclonic epilepsy POLG SCN1A Bolszak et al. (2009)
Progressive external ophthalmoplegia POLG SLC25A4 Galassi et al. (2008)
Bartter syndrome CLCNKA CLCNKB Nozu et al. (2008)
Chronic pancreatitis SPINK1 CASR or CFTR or CTRC or
PRSS1
Felderbauer et al. (2003), Masson et al. (2007),
Tzetis et al. (2007), Schneider et al. (2011),
LaRusch et al. (2012) and Rosendahl et al.
(2013)
Oculocutaneous albinsim OCA2 TYRP1 or SLC45A2 or TYR Chiang et al. (2008) and Wei et al. (2013)
Oculocutaneous albinsim TYR SLC45A2 Wei et al. (2013)
Cystinuria SLC3A1 SLC7A9 Font-Llitjo´s et al. (2005)
Transposition of the great arteries ZIC3 FOXH1 or NKX2-5 De Luca et al. (2010)
Congenital heart disease MYH6 NKX2-5 or GATA4 Granados-Riveron et al. (2012)
Charcot–Marie–Tooth disease* PMP22 ABCD1 or LITAF Meggouh et al. (2005), Hodapp et al. (2006)
Charcot–Marie–Tooth disease GJB1 EGR2 Chung et al. (2005)
Charcot–Marie–Tooth disease* GDAP1 MFN2 Vital et al. (2012)
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reductase deficiency (Draper et al. 2003). It would not be
altogether surprising, in conditions where digenic or even
trigenic inheritance has been reported, if the individual
component mutations were found to exhibit a reduced
clinical penetrance as compared to mutations underlying
the monogenic forms of the disease.
In some disorders, incomplete penetrance of a particular
mutation can be due to the oligogenic nature of the disease
and hence to the requirement for multiple genes to be
mutated for the condition in question to manifest. An
inherited predisposition to cancer can be monogenic, but is
also very likely to have an oligogenic aetiology in many
instances (Fearnhead et al. 2004; Koren-Michowitz et al.
2005; Okkels et al. 2006; Ku¨ry et al. 2008; Wasielewski
et al. 2010; Martinez and Kolodner 2010; Plon et al. 2011;
Morak et al. 2011; Gracia-Aznarez et al. 2013). In
Table 4 continued
Disease Gene 1 Gene 2 Reference
Refractory auto-inflammatory syndrome TNFRSF1A CIAS1 Touitou et al. (2006)
Short-rib polydactyly syndrome type 2 NEK1 DYNC2H1 Thiel et al. (2011)
Maturity-onset diabetes of the young HNF1A HNF1B Karges et al. (2007)
Maturity-onset diabetes of the young HNF1A HNF4A Forlani et al. (2010) and Shankar et al. (2013)
Polycystic kidney disease* PKD1 PKD2 Pei et al. (2001) and Dedoussis et al. (2008)
Hyperimmunoglobulinaemia D and periodic
fever syndrome
MVK TNFRSF1A Hoffmann et al. (2005)
Obesity, hyperinsulinaemia and insulin
resistance
TCF1 NROB2 Tonooka et al. (2002)
Progressive external ophthalmoplegia POLG C10orf2 Van Goethem et al. (2003)
Neuronal ceroid lipofuscinosis POLG CLN5 Staropoli et al. (2012)
Chronic lung disease SFTPC ABCA3 Bullard and Nogee (2007)
Lafora disease EPM2B PPP1R3C Guerrero et al. (2011)
Congenital erythropoietic porphyria UROS ALAS2 To-Figueras et al. (2011)
Familial venous thrombosis* PROC PROS1 Formstone et al. (1996), Brenner et al. (1996),
Boinot et al. (2003), Knoll et al. (2001) and
Hayashida et al. (2003)
Familial venous thrombosis* PROC SERPIND1 Bernardi et al. (1996)
Breast cancer* BRCA1 BRCA2 Leegte et al. (2005), Lavie et al. (2011) and
Heidemann et al. (2012)
Breast cancer BRCA1 PALB2 Pern et al. (2012)
Multiple tumours of different types BRCA1 MLH1 Pedroni et al. (2013)
Familial pulmonary arterial hypertension BMPR2 THBS1 Maloney et al. (2012)
Hereditary nonpolyposis colorectal cancer MUTYH MSH6 Van Puijenbroek et al. (2007) and Gira´ldez et al.
(2009)
Colorectal cancer EPCAM MSH2 Li-Chang et al. (2013)
Colorectal cancer, juvenile onset* APC MSH2 Uhrhammer and Bignon (2008)
Autoimmune lymphoproliferative syndrome FAS CASP10 Cerutti et al. (2007)
Autoimmune lymphoproliferative syndrome* FAS PRF1 Clementi et al. (2004)
Steroid-resistant focal segmental
glomerulosclerosis
NPHS2 NPHS1 or CD2AP Lo¨wik et al. (2008)
Severe infantile liver disease AKR1D1 SKIV2L Morgan et al. (2013)
Ataxia, dementia and hypogonadotropism RNF216 OTUD4 Margolin et al. (2013)
Paediatric inflammatory bowel disease NOD2 GSDMB or ZNF365 or
ERAP2 or SEC16A or
GMPBB
Christodoulou et al. (2013)
Paediatric inflammatory bowel disease BACH2 IL10 Christodoulou et al. (2013)
Hutchinson-Gilford progeria syndrome ZMPSTE24 LMNA Denecke et al. (2006)
In this table, we considered only those examples of digenic mutations that are unlikely to be merely coincidental and which are predicted to affect
genes that are both functionally associated with the disease in question
* Patients, with heterozygous mutations affecting two different genes, exhibiting earlier disease onset or a more severe clinical phenotype than
either of their singly heterozygous parents or their siblings
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amyotrophic lateral sclerosis, van Blitterswijk et al.
(2012a) detected FUS and TARDBP mutations in combi-
nation with ANG mutations, and C9orf72 repeat expansions
with TARDBP, SOD1 and FUS mutations. At least five
relatively common polymorphisms in four different genes,
CFB (Arg32Gln, rs641153), C2 (Glu318Asp, rs9332739),
CFH [Tyr402His (rs1061170) and non-coding variant
rs1410996] and ARMS2 (Ala69Ser, rs10490924), interact
so as to confer increased risk of age-related macular
degeneration (Maller et al. 2006). Common polymorphisms
in the LEPR (Gln223Arg, rs1137101) and ADRB2
[Arg16Gly (rs1042713) and Gln27Glu (rs1042714)] genes
jointly confer increased risk of obesity even though none of
these polymorphisms exhibits a significant influence on
their own (Pereira et al. 2011). Other examples of oligo-
genic inheritance, involving the mutation or polymorphism
of multiple unlinked genes in the same individual, include
isolated gonadotropin-releasing hormone deficiency
(KAL1, PROK2 and NELF; Sykiotis et al. 2010), hypertrophic
cardiomyopathy (MYH7, MYBPC3, TNNI3 and TNNT2;
Girolami et al. 2010; Lopes et al. 2013), iminoglycinuria
(SLC36A2, SLC6A20, SLC6A18, SLC6A19; Bro¨er et al. 2008),
long QT syndrome (KCNH2, SCN5A and KCNE1; Yoshikane
et al. 2013), chronic pancreatitis (SPINK1, CFTR and CTRC;
Rosendahl et al. 2013), atypical haemolytic uraemic syndrome
(CFH, CD46 and CFI; Roumenina et al. 2012; Bresin et al.
2013), Parkinson disease (LRRK2, SNCA, MAPT, GBA, BST1,
PARK16; Wang et al. 2012), acrocallosal syndrome (KIF7,
AHI1, BBS2 and BBS4; Walsh et al. 2013), autism spectrum
disorders (Neale et al. 2012) and a low plasma level of HDL
cholesterol, a major risk factor for atherosclerosis (Cohen et al.
2004; Wang et al. 2008; Johansen and Hegele 2012).
One of the best characterized oligogenic disorders is
Bardet–Biedl syndrome (BBS) where at least 17 genes are
known to contribute to the clinical phenotype, and the
severity of the disease phenotype may vary as a result of
the interaction of mutations in different BBS genes.
Although mutations at more than one locus have often been
found to segregate with the disease, thereby modulating
both its penetrance and expressivity (Badano et al. 2006;
Zaghloul and Katsanis 2009; Cardenas-Rodriguez et al.
2013), the jury is still out in relation to claims of digenic
triallelic inheritance in BBS (Katsanis et al. 2001; Beales et al.
2003; Badano et al. 2003; Fauser et al. 2003; Smaoui et al.
2006; Chen et al. 2011; Abu-Safieh et al. 2012). This not-
withstanding, some common BBS gene variants appear to be
detrimental to protein function and may well interact with the
much rarer pathogenic BBS mutations so as to influence the
severity of the BBS phenotype (Zaghloul et al. 2010).
Some idea of the likely complexity of genotype–phe-
notype relationships in complex disease has come from the
comparative exome sequencing of 237 ion channel genes
performed in sporadic idiopathic epilepsy patients and
unaffected controls (Klassen et al. 2011). Both rare and
common variants were identified in the two groups.
Although these variants were more numerous in the patient
group, they were not found to be predictive of disease: as
the authors opined, ‘‘absolute numerical counts of SNP
burden hold little predictive value as a global pathogenic
measure’’. However, 51 % of cases and 14 % of controls
had C2 non-synonymous variants in their sodium channel
genes. In similar vein, 24 % of cases and 6 % of controls
had C2 non-synonymous variants in their GABA receptor
alpha genes (Klassen et al. 2011). Such findings are quite
consistent with an oligogenic model of sporadic epilepsy
(Dibbens et al. 2007). What is required here, however, is
not a simple variant number count, but rather an assess-
ment, on an individual basis, of the net effect of an oli-
gogenic variant profile (requiring ascertainment of the
various gains or losses of function associated with specific
variants and computed with an eye to the nature of
potential joint effects) on a clinically or phenotypically
relevant output measure such as the electrical signature of a
cell type or brain region.
Perhaps, the best characterized oligogenic disorder to
date is familial venous thrombosis. The risk of venous
thromboembolism is known to be increased in patients who
carry more than one genetic variant disrupting the 100?
genes of the ‘hemostaseome’ (Fechtel et al. 2011). Thus,
19 % of symptomatic individuals harbouring a protein C
(PROC) gene mutation were also found to be heterozygous
for factor V Leiden (F5 Arg534Gln; Koeleman et al. 1994),
a functional polymorphism which occurs at a frequency of
2–5 % in European populations. In a replication study,
9.5 % of venous thrombosis patients were found to carry
both mutations (Gandrille et al. 1995) suggesting that their
co-occurrence increases the likelihood of their coming to
clinical attention. Similar findings have been noted in
families with protein S (PROS1) deficiency; among
symptomatic individuals, 38 % also carried the factor V
Leiden mutation (Koeleman et al. 1995). Likewise, coin-
heritance of antithrombin (SERPINC1) deficiency and
factor V Leiden not only increases clinical penetrance, but
also reduces the age of clinical presentation (van Boven
et al. 1996). In a larger-scale study involving 132
thrombophilic families, the risk of thrombosis was
increased and the age of onset lowered in cases of double
heterozygosity for two gene variants (combinations of
variants in PROC, PROS1, F5 and F2) as compared to
individuals carrying single variants of these genes (Tirado
et al. 2001). ABO blood group is also known to modify the
risk of venous thrombosis in individuals with hereditary
thrombophilia through an influence on the plasma levels of
factor VIII and the factor VIII carrier protein, von Wille-
brand factor (Tirado et al. 2005; Nossent et al. 2006; Cohen
et al. 2012). Such studies provide strong circumstantial
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support for the joint impact of multiple mutations in
thrombotic disease (Martinelli et al. 2008). The elevation
of risk for each individual variant is, however, low, and
incomplete penetrance is evident for all prothrombotic
variants. This means that the vast majority of individuals
bearing these variants do not suffer from thrombotic dis-
ease. It is nevertheless reasonable to suppose that patients
with recurrent venous thrombosis will tend to have a
greater number of prothrombotic variants than those who
have experienced a single thrombotic event, with those
individuals who never experienced thrombosis harbouring
even fewer prothrombotic variants (Fechtel et al. 2011).
Since the number of genes known to influence haemostasis
is large and the number of variants with potential impact
larger still, we may expect that a substantial number of
different variant combinations will be capable of confer-
ring an increased risk. This genetic risk will accompany
each prothrombotic challenge (such as pregnancy, long
haul air travel, contraceptive pill usage and immobilization
after surgery), with the greatest risk of venous thrombosis
accruing to those possessing the largest number of pro-
thrombotic variants in their genomes (Fechtel et al. 2011).
Our task is to come to understand how specific DNA
sequence changes in the large number of genes known to
play a role in haemostasis and thrombosis act either syn-
ergistically or antagonistically so as to confer disease
predisposition upon the individual, thereby influencing the
clinical penetrance, by shifting their haemostatic balance
towards either a prothrombotic or anticoagulant phenotype
(Franchini and Mannucci 2009; Westrick and Ginsburg
2009; Fechtel et al. 2011).
Influence of sex on penetrance
The sex dependence of the penetrance of inherited mutations
has been reported in a variety of different heritable disorders
including haemochromatosis (HFE; Rossi et al. 2008),
hypertrophic cardiomyopathy (MYBPC3, MYH7; Michels
et al. 2009; Page et al. 2012), arrhythmogenic right ventricular
dysplasia/cardiomyopathy (PKP2; Dalal et al. 2006), long QT
syndrome (KCNQ1, KCNH2, SCN5A; Zareba et al. 2003),
hypokalaemic periodic paralysis (CACNA1S; Kawamura et al.
2004; Li et al. 2012; SCN4A; Ke et al. 2013), familial pul-
monary arterial hypertension (BMPR2; Austin et al. 2009b),
hereditary spastic paraplegia (SPAST; Mitne-Neto et al.
2007), hereditary dystonia/dopa-responsive dystonia (GCH1;
Furukawa et al. 1998), cardiac disease (LMNA; van Rijsingen
et al. 2013), Hirschsprung disease (RET; Emison et al. 2005),
autism spectrum disorder (SHANK1; Sato et al. 2012),
amyotrophic lateral sclerosis (C9ORF72; Le Ber et al. 2013;
Williams et al. 2013) and familial obesity (SHP; Yang et al.
2010). A male-biased effect on the penetrance of duplications
and deletions at 16p13.11 is evident in a range of neorode-
velopmental conditions including autism, attention deficit
hyperactivity disorder, intellectual disability and schizophre-
nia (Tropeano et al. 2013). In the case of familial pulmonary
arterial hypertension, both genetic and metabolic marker data
were consistent with a modifying role for variation in oes-
trogens and/or oestrogen metabolism upon disease risk
(Austin et al. 2009b). The low penetrance of hypokalaemic
periodic paralysis due to SCN4A mutations in females is also
likely to be due to the effect of oestrogens (Ke et al. 2013).
Allelic variation may also influence the clinical phenotype
in a sex-specific fashion. Thus, Lahtinen et al. (2011) reported
that the common KCNE1 Asp85Asn (rs1805128) polymor-
phism was associated with a QT-interval prolongation in male
but not female type 1 long QT syndrome patients harbouring
the KCNQ1 Gly589Asp mutation. KCNE1 Asp85Asn may
thus be a sex-specific QT-interval modifier in type 1 LQTS.
Similarly, the Ile148Met (rs738409) PNPLA3 polymorphism
is a disease modifier in primary sclerosing cholangitis with bile
duct stenosis, but only in male patients (Friedrich et al. 2013).
Finally, a Val89Leu polymorphism (rs523349) in the steroid
5a-reductase type 2 (SRD5A2) gene, which serves to reduce
the conversion of testosterone to dihydrotestosterone, has been
claimed to influence the severity of post-traumatic stress
symptoms but in a male-specific fashion (Gillespie et al. 2013).
An intriguing parent-of-origin effect has been noted in
two apparently unrelated retinoblastoma families with a
heterozygous, low-penetrance splice site mutation
(c.607?1G[T) in the RB1 gene which causes skipping of
exon 6 (Klutz et al. 2002). The abundance of the resulting
nonsense (frameshifted) RB1 mRNA relative to the wild-
type was found to vary between members of one and the
same family. Those individuals in family #1 who inherited
the mutant RB1 allele from their mother displayed a similar
level of nonsense and wild-type RB1 transcripts, and only
one of eight carriers developed retinoblastoma. By contrast,
those individuals in family #2 who inherited the mutant RB1
allele from their fathers displayed a reduced abundance of
the nonsense transcript with six of eight carriers developing
retinoblastoma, indicating that the mutant transcript has
residual function. Assuming that this is not a chance result
(Fisher’s exact test; p = 0.04), it may be that the gender of
the transmitting parent can influence the penetrance of the
pathogenic mutation.
There is good evidence to suggest that sex-specific
genomic architecture can influence the expression of
human phenotypes, including disease traits (Ober et al.
2008). It is likely that the underlying mechanism is dif-
ferential gene regulation in males and females, particularly
in relation to sex steroid-responsive genes (Zhang et al.
2007; Dimas et al. 2012).
Another mechanism by which sex influences penetrance
is via genomic imprinting. Genomic imprinting results
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from the epigenetic modification of a gene or gene region
that leads to the mutually exclusive expression of either the
maternal or the paternal allele. Imprinted alleles are
silenced (by DNA methylation or histone modification), so
that the corresponding genes are expressed only from the
non-imprinted allele inherited from the other parent. In the
case of disease genes, imprinting can influence the pene-
trance of pathological mutations depending upon whether
the wild-type or the mutant allele is imprinted. Genomic
imprinting can give rise to markedly different levels of
clinical penetrance depending upon the parental origin of
the disease allele. Examples include SGCE mutations in
myoclonus dystonia (Zimprich et al. 2001; Mu¨ller et al.
2002; Grabowski et al. 2003) and SDHD mutations in
paraganglioma (Badenhop et al. 2001; Simi et al. 2005;
Baysal et al. 2011). In both cases, maternal imprinting
ensures that the pathologically effective mutations are
almost invariably inherited from the father. Intriguingly, in
one family with pseudohypoparathyroidism type 1b, Jan de
Beur et al. (2003) reported a case of the incomplete pene-
trance of an imprinting mutation. These authors found that
both the clinically affected and unaffected siblings had
inherited the same GNAS1 allele from their affected mother,
indicating that some dissociation must have occurred
between the genetic GNAS1 defect responsible for the disease
and its epigenetic mark. The inconsistent acquisition of a
paternal epigenotype on a maternal GNAS1 allele would
appear to provide evidence for the incomplete expression of a
reprogramming defect that affects imprinting.
Age-dependent penetrance
Age-dependent penetrance is present if the clinical symp-
toms of a given disease are increasingly likely to manifest
themselves with increasing age of the at-risk individual.
Age-dependent penetrance has been reported for mutations
in a wide variety of different human disease genes, e.g.
MYBPC3 in hypertrophic cardiomyopathy (Michels et al.
2009; Page et al. 2012), LMNA in Emery–Dreifuss mus-
cular dystrophy (Vytopil et al. 2002), MC4R in familial
obesity due to melanocortin-4 receptor deficiency (Stutz-
mann et al. 2008), GBA in Parkinson disease (Anheim et al.
2012; Rana et al. 2013), BRCA1 and BRCA2 in breast
cancer susceptibility (Chen and Parmigiani 2007; Al-Mulla
et al. 2009; Mavaddat et al. 2013), MEN1 in multiple
endocrine neoplasia type 1 (Machens et al. 2007), RET in
multiple endocrine neoplasia type 2A (Frank-Raue et al.
2011) and SDHD and SDHB in predisposition to paragan-
gliomas (Hensen et al. 2010; Hes et al. 2010). The APOE
e4 allele (comprising the T allele of rs429358 and the C
allele of rs7412 in cis) serves to reduce the age of onset of
Alzheimer disease from 78.4 years in patients lacking the
allele, to 75.3 in heterozygous carriers to 72.9 in carriers of
two APOE e4 alleles (Sando et al. 2008).
Age-dependent penetrance is particularly evident where
large numbers of heterozygous carriers harbouring specific
gene mutations have been identified by cascade screening,
e.g. LRRK2 Gly2019Ser (rs34637584) in Parkinson disease
(Latourelle et al. 2008; Healy et al. 2008; Sierra et al.
2011), GLUT1 Arg232Cys in familial idiopathic general-
ized epilepsy (Striano et al. 2012), RET Cys634Trp
(rs77709286) in multiple endocrine neoplasia type 2A
(Milos et al. 2008), ACADM Lys329Glu (rs77931234) in
medium-chain acyl-CoA dehydrogenase deficiency (And-
resen et al. 2012), PKP2 Gln59Leu in arrhythmogenic right
ventricular cardiomyopathy (Lahtinen et al. 2008) and
MYBPC3 c.2308?1G[A (rs112738974) in hypertrophic
cardiomyopathy (Oliva-Sandoval et al. 2010). However,
there are always anomalous cases; thus, in a family seg-
regating a pathogenic missense mutation (Arg1205His) in
the vacuolar protein sorting 35 (VPS35) gene, six family
members between the ages of 54 and 73 years exhibited
signs of Parkinson disease, but one individual was still
asymptomatic at age 86 (Nuytemans et al. 2013).
Specific mutations may sometimes differ from each
other in terms of the average age of onset of clinical
symptoms. Thus, for example, patients with maturity-onset
diabetes of the young (MODY) who harbour mutations in
exons 9 or 10 of the HNF4A gene have been found to
develop disease much later (average 40 vs. 24 years) than
MODY patients with mutations in exons 2-8 (Harries et al.
2008). This difference in age-related penetrance is thought
to be a consequence of the exon 9 and 10 mutations being
absent from three of the nine HNF4A isoforms encoded by
the HNF4A gene, whereas the mutations located in exons
2–8 affect all nine isoforms.
In some cases, the clinical penetrance of a particular
mutation can change quite dramatically with age. For
example, the cumulative incidence among carriers of the
Arg1441Gly mutation in the LRRK2 gene causing Parkin-
son disease was found to be 12.5 % until the age of
65 years, but 83 % until age 80 (Ruiz-Martı´nez et al.
2010). However, the penetrance of the common TTR
Val30Met mutation causing autosomal dominant familial
amyloid polyneuropathy has been estimated to be 1.7 %
until the age of 30 years, 22 % until the age of 60, but still
only 69 % until age 90 (Hellman et al. 2008). Majounie
et al. (2011) showed that the pathogenic GGGGCC hexa-
nucleotide expansion in the C9orf72 gene associated with a
high proportion of cases of amyotrophic lateral sclerosis
and frontotemporal dementia was non-penetrant in indi-
viduals younger than 35 years, 50 % penetrant by age 58
but almost fully penetrant by age 80. Age-dependent pen-
etrance could thus provide another explanation for why
some putatively pathological mutations listed in HGMD
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are present in apparently healthy individuals from the 1000
Genomes Project.
A glimpse of the way ahead is provided by a recent
study of symptomatic and asymptomatic carriers of a
specific granulin (GRN) mutation (Thr272Ser) responsible
for autosomal dominant frontotemporal lobar degeneration
(FTLD), a disease whose onset typically occurs in the sixth
decade of life (Milanesi et al. 2013). Unsurprisingly, both the
symptomatic and asymptomatic GRN mutation carriers had
lower serum levels of progranulin than non-carriers. However,
using whole-genome microarray analysis, the leukocyte
expression of the TMEM40 and LY6G6F genes was found to
be significantly higher in FTLD patients harbouring GRN
mutations as compared to asymptomatic carriers. Further,
elevated expression of the genes was correlated with increased
brain damage and could therefore be directly related to the
pathology of the disease (Milanesi et al. 2013).
Epigenetic influences on disease penetrance
As briefly discussed above in the context of the influence of
gender upon penetrance, epigenetic modifications may also
account for incomplete penetrance. Thus, when monozy-
gotic twins are discordant for disease phenotypes, epige-
netic differences should be considered (Wong et al. 2005;
Kaminsky et al. 2009; Gordon et al. 2011; 2012). Indeed,
monozygotic twins have been reported who differ both in
relation to a specific clinical phenotype and in terms of an
epigenotype. For example, monozygotic twins discordant
for childhood leukaemia have been found to have discor-
dant BRCA1 methylation status (Galetzka et al. 2012).
Similarly, hypermethylation of SLC6A4, encoding the
serotonin transporter, has been reported in one member of a
monozygotic twin pair discordant for bipolar disorder
(Sugawara et al. 2011).
Epigenetic differences may also contribute to incom-
plete penetrance in other conditions such as asthma, where
DNA methylation has been reported to modulate the risk of
disease conferred by genetic variants at the zona pellucida
binding protein 2 (ZPBP2; Berlivet et al. 2012), forkhead
box P3 (FOXP3; Runyon et al. 2012), interferon-c (IFNG;
Runyon et al. 2012) and interleukin-4 receptor (IL4R; Soto-
Ramı´rez et al. 2013) gene loci.
A special case of imprinting is provided by X-inacti-
vation (Dobyns et al. 2004). When a disease gene is
X-linked, skewed X-inactivation can cause variable pene-
trance of pathogenic mutations in female carriers (Van den
Veyver 2001). Examples of this phenomenon involve
mutations in the TIMM8A gene (Xq22.1) in dystonia-
deafness syndrome (Plenge et al. 1999), the EBP gene
(Xp11.23) in X-linked dominant chondrodysplasia punctata
(Shirahama et al. 2003), the FLNA gene (Xq28) in
otopalatodigital type 1 syndrome (Hidalgo-Bravo et al.
2005), the ABCD1 gene (Xq28) in a family with X-linked
adrenoleukodystrophy (Wang et al. 2013b) and the ZIC3
gene (Xq26.3) in a family with complex heart defects
(Chhin et al. 2007). It should, however, be pointed out that
some ZIC3 mutations are characterized by reduced pene-
trance in males, a finding that cannot be explained by
skewed X-inactivation (Me´garbane´ et al. 2000).
Gene–environment interactions and penetrance
The environment, in its broadest sense, will often influence
clinical penetrance, either ameliorating or exacerbating the
impact of heritable genetic variants (Hunter 2005). Indeed,
environmental modifiers of disease penetrance (e.g. diet,
alcohol intake, drugs, metabolic syndrome) have long been
known to influence the penetrance of HFE C282Y homo-
zygosity in haemochromatosis (Beutler 2003; Rossi et al.
2008; Deugnier and Mosser 2008).
One way to explore the relative contribution of genes
and environment is by studying monozygotic twins har-
bouring the same pathogenic mutation(s) and sharing the
same genetic background. Although the vast majority of
such monozygotic twin pairs have been found to be con-
cordant in terms of their clinical phenotypes (e.g. Miesfeldt
et al. 1998; Munhoz et al. 2008; McDade et al. 2012),
others are quite discordant (Matsuo et al. 2000; Amann
et al. 2001; Martin et al. 2003; Holmgren et al. 2004;
Lachmann et al. 2004; Czlonkowska et al. 2009; Bieg-
straaten et al. 2011; Fencl et al. 2012; Iatropoulos et al.
2012), suggesting that the environment can often play an
important role in determining both the penetrance and
expressivity of pathological mutations. [It should be borne
in mind that there are various alternative genetic explana-
tions for discordant phenotypes in monozygotic twins,
including de novo post-zygotic mutation (Kentsis et al.
2009; Vogt et al. 2011), compensatory mutations (Mankad
et al. 2006) and somatic copy number variation (Bruder
et al. 2008) that obviate the need for a major contribution
from the environment, as well as acquired epigenetic dif-
ferences (Galetzka et al. 2012; Bennett et al. 2008)].
An environmental influence on penetrance is perhaps at
its most evident in cancer susceptibility (Houlston and Peto
2004; Shen 2009). Indeed, an environmental component is
very important in colorectal cancer where inherited genetic
variants at a number of different loci interact primarily
with dietary variables and overweight to confer risk (Hutter
et al. 2012; Siegert et al. 2013). In similar vein, inherited
differences in skin pigmentation influence the risk of
melanoma, but this risk is further modified both by latitude
of habitation and lifestyle choices (van der Velden et al.
2001; Bishop et al. 2002; Begg et al. 2005; Meyle and
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Guldberg 2009; Scherer and Kumar 2010). Parity and
breast feeding are both known to be modifiers of risk of
breast/ovarian cancer in BRCA1 mutation carriers
(McLaughlin et al. 2007; Jernstro¨m et al. 2004; Cullinane
et al. 2005; Antoniou et al. 2006). Another example of a
gene–environment interaction in the context of cancer is
provided by cytochrome P450 gene variants that may
influence cancer risk by virtue of their roles in xenobiotic
metabolism, detoxification of carcinogens, and to a lesser
extent the bioactivation of procarcinogens (Rodriguez-
Antona et al. 2010). Lung cancer provides an excellent
example of the interaction of genes and environment.
Three different GWAS, published virtually simultaneously,
provided the first convincing evidence for an association
between heritable genetic variation at the nicotinic ace-
tylcholine receptor CHRNA5/CHRNA3/CHRNB4 locus on
chromosome 15q25.1 and lung cancer (Amos et al. 2008;
Hung et al. 2008; Thorgeirsson et al. 2008). Although allele
T of SNP rs1051730, a synonymous variant located within
exon 5 of the CHRNA3 gene, was found to be strongly
associated with smoking quantity, the issue of whether the
association with lung cancer was direct or indirect (i.e.
mediated through cigarette smoking and nicotine depen-
dence) remained unclear. Galvan and Dragan (2009) per-
formed a meta-analysis of reported studies of the 15q25
region and found that this locus was not associated with
lung cancer risk in never-smokers. This lack of effect
argued for an indirect effect of genetic variation at the
15q25 locus on lung cancer risk via an association between
these variants and smoking/nicotine dependence. However,
Wang et al. (2010b) subsequently examined the relation-
ship between rs1051730 and lung cancer and concluded
that, in addition to its indirect influence on disease risk
(through smoking behaviour), this variant also exerted a
rather larger (and direct) effect. Kaur-Knudsen et al. (2011)
concurred, demonstrating that homozygosity for rs1051730
was associated with a smoking behaviour-adjusted relative
risk of lung cancer of 1.6, indicating that rs1051730 is
associated with an additional risk of lung cancer over and
above that derived from its effect on smoking behaviour.
Finally, in a lung cancer case–control study, VanderWeele et al.
(2012) employed two 15q25.1 SNPs, rs8034191 and
rs1051730, to show that the proportion of increased risk due to
smoking was only 3.2 % and that the association of the 15q25
variants with lung cancer operates primarily through pathways
other than smoking behaviour. All of the above notwithstand-
ing, the risk of lung cancer conferred directly or indirectly by
genetic variants on 15q25 would be small if the individual
concerned simply opted not to smoke (Brennan et al. 2011).
The penetrance of genetic variants conferring suscepti-
bility to infectious disease is clearly contingent upon
exposure to the specific pathogens concerned (Vannberg
et al. 2011; Chapman and Hill 2012). One example is the
CCR5 32-bp (c.554del32) deletion which is associated with
a lower rate of HIV infection and a delay in the onset of
AIDS (Smith et al. 1997). Sex may also play a role in some
conditions; thus, in multiple sclerosis, women appear to be
more responsive to the environmental risk factors that
cause the disease (Goodin 2012; O’Gorman et al. 2012).
Diet is also an important modifier of clinical penetrance.
Thus, an inherited predisposition to obesity (exemplified by
the association between dietary fat intake and obesity in
carriers of the PPARG2 Pro12Ala allele; Memisoglu et al.
2003) is in principle modifiable by diet (Walters et al.
2010; Ramachandrappa and Farooqi 2011). Similarly, the
impact of genetic variants at the FTO locus on risk of
obesity can be attenuated by physical activity (Kilpela¨inen
et al. 2011). Diet is also an important modifier of clinical
penetrance in phenylketonuria, as mentioned in the
‘‘Introduction’’ to this review, where the penetrance of the
condition can be very substantially reduced by restricting
dietary phenylalanine (van Spronsen 2010).
Heavy coffee drinkers have been known for some time
to have a reduced risk of developing Parkinson disease.
However, the risk of developing Parkinson disease has
been found to be reduced even further for heavy coffee
drinkers by a specific variant in the GRIN2A gene; com-
pared to light coffee drinkers with an rs4998386_CC
genotype, heavy coffee drinkers with the same genotype
have an 18 % lower risk, whereas heavy coffee drinkers
with an rs4998386_TC genotype have a 59 % lower risk
(Hamza et al. 2011).
More unusually, altitude has been reported to act as a
modifier of the phenotypic severity of hereditary paragan-
glioma type 1 caused by mutations in the succinate dehy-
drogenase D (SDHD) gene (Astrom et al. 2003). Since
chronic hypoxic stimulation at high altitude causes spo-
radic carotid body paragangliomas, Astrom et al. (2003)
proposed that SDHD might be involved in oxygen sensing.
Thus, whilst SDHD mutations could impair oxygen sens-
ing, low altitude may serve to reduce the penetrance of
these mutations.
The clinical penetrance of psychological disorders and
traits has long been known to be strongly influenced by
gene–environment interactions (Dick 2011). For example,
a 44-bp deletion/insertion polymorphism in the promoter
region of the serotonin transporter gene SLC6A4 was
reported to be associated with depression after stressful life
events (Caspi et al. 2003). Recently, Klengel et al. (2013)
gave us a glimpse of the likely complexity of the mecha-
nisms underlying gene–environment interactions in the
context of psychological disorders. These authors demon-
strated that a risk variant for post-traumatic stress disorder
and major depression in the FK506-binding protein 5 gene
(FKBP5) is demethylated in several cell types in children
exposed to trauma. This demethylation persists into
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adulthood and confers an increased risk of developing
disease. In FKBP5 risk allele carriers, excessive cortisol
release during early life stress leads to demethylation
within the glucocorticoid-responsive elements of FKBP5 in
intron 7 with the consequence of long-lasting disruption of
the ultra-short feedback loop that balances FKBP5 and
glucocorticoid receptor activity, causing dysregulation of
the stress hormone system. The FKBP5 risk allele corre-
sponds to a functional polymorphism located in intron 2 of
the FKBP5 gene that alters the chromatin interaction
between the transcriptional start site and long-range
enhancers, thereby increasing the transcriptional activity of
FKBP5 over and above that of the wild-type allele. Only
the risk allele is able to form a three-dimensional complex
which includes RNA polymerase II and a glucocorticoid-
responsive element located within intron 7 of FKBP5.
Enhanced transcription of the risk allele facilitates the
PolII-dependent demethylation in intron 7 in response to
elevated glucocorticoids under early life stressful condi-
tions. The reduced methylation of intron 7 CpGs leads to
increased induction of FKBP5 by glucocorticoid receptor
activation, especially in risk allele carriers, representing an
enhancement of the ultra-short feedback loop leading to
increased glucocorticoid receptor resistance. If this occurs
during developmentally critical periods, then the methyla-
tion patterns will remain stable over time (Klengel et al.
2013). Hence, the demethylation in FKBP5 intron 7
depends upon both childhood trauma and the sequence
variant in intron 2, in a tripartite gene–environment inter-
action (Szyf 2012).
The above examples represent the tip of the iceberg
because the clinical penetrance of most monogenic con-
ditions and all complex disease is likely to be influenced by
the environment in some way or another. A further glimpse
of this complexity is perhaps provided by Kallberg et al.
(2007) who reported interactions between HLA-DRB1 SE
alleles, the A allele of the PTPN22 Arg620Trp (rs2476601)
polymorphism and smoking in conferring risk of rheuma-
toid arthritis. Gene–environment interactions are also evi-
dent in asthma (Custovic et al. 2012; Chang et al. 2012)
and eczema (Bisgaard et al. 2008) and will become
increasingly apparent in other disorders as new techniques
are developed to identify them (Aschard et al. 2012). To
this end, mouse models are beginning to come into their
own as a means to study the role of gene–environment
interactions in the aetiology of human disorders; by these
means, short-term gestational hypoxia has been found to
increase the penetrance of vertebral defects in congenital
scoliosis (Sparrow et al. 2012).
Conclusions
A holy grail of human medical genetics is to be able to
deduce the likely clinical phenotype of an individual from
their genotype or genomic sequence. It was once perhaps
naively assumed that, at least for ‘‘monogenic’’ disorders,
genotype–phenotype relationships would be that simple,
and also fairly straightforward to discern. However, it has
been clear for some time that it is inappropriate to regard
such disorders as either simple or monogenic in any strict
sense. Further, in many cases, the reality is that we cannot
readily draw straight lines of causation from known
genotypes to specific clinical phenotypes. This is because
instances abound of individuals who harbour a disease-
associated mutation/genotype, but who do not express
certain features of the disease or who may even be asymp-
tomatic. This phenomenon of reduced penetrance may or may
not be the norm, but it is far from being a rare exception. Our
appreciation of its full extent is still emerging, although some
of the different mechanisms underlying reduced penetrance
are now becoming apparent (Fig. 1).
It has become clear from large-scale sequencing studies
that many individuals in the general population harbour
Fig. 1 Some of the different
mechanisms underlying the
phenomenon of reduced
penetrance in human inherited
disease
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large numbers of potentially disadvantageous variants
without suffering any obvious ill effects (The 1000 Gen-
omes Project Consortium 2010; MacArthur et al. 2012;
Xue et al. 2012; Shen et al. 2013a). Thus, it would appear
that many mutations are, on their own, insufficient to cause
disease and need to occur in the presence of other genetic
variants, either allelic or non-allelic, as well as facultative
environmental factor(s), for a disease state to ensue. Indeed,
many pathological mutations may only be conditionally
pathogenic, exerting a detrimental effect only if and when the
genetic and external environments interact to push the phe-
notype over some notional threshold into pathology.
Penetrance is best thought of as being a genotype-spe-
cific rather than a gene-specific or disease-specific phe-
nomenon. Thus, in any given disease gene, some mutations
may exhibit complete penetrance, whereas others may
show incomplete or even quite low penetrance. Generally
speaking, mutations that display low penetrance also tend
to exert milder effects on the clinical phenotype and/or
protein function, while the more highly penetrant a muta-
tion is, the less frequent it is likely to be in the general
population (Coventry et al. 2010; Marth et al. 2011; Gorlov
et al. 2011; Tennessen et al. 2012; Nelson et al. 2012;
Subramanian 2012; Fu et al. 2013). Whereas highly
penetrant mutations may exert their pathogenic effects with
relatively little interaction with other genetic or environ-
mental factors, low-penetrance mutations are generally
characterized by significant gene–gene and gene–environ-
ment interactions (Cordell 2009). Different combinations
of such variants may contribute to the variable penetrance
characteristic of both monogenic and complex disease.
Whatever the molecular basis may be in the case of a
given mutation, reduced penetrance is in general likely to
present a serious impediment to the implementation of any
scheme designed to classify the pathological significance
of human genetic variants (e.g. Plon et al. 2008; Tavtigian
et al. 2008). Reduced penetrance is also likely to present
problems in identifying pathological mutations in whole-
genome/exome sequencing programmes unless it is
explicitly built into the disease models being considered
(Varga et al. 2013). Despite the complexities it introduces,
it also offers hope in the sense that if we are able to identify
environmental factors, drugs or other types of intervention that
serve to reduce the penetrance of a given pathological variant,
or alternatively delay the onset of its pathological sequelae
beyond the natural lifespan of its carrier, we shall have a whole
new range of therapeutic approaches at our disposal.
Human genetic variation occurs as a continuum ranging
from neutral polymorphisms, through functional polymor-
phisms and disease susceptibility variants to true patho-
logical mutations with high penetrance. However, in
addition and as discussed above, it has become increasingly
clear that our genomes contain many ‘putatively
disadvantageous variants’ that are probably insufficient on
their own to cause disease, but nevertheless still have the
potential to contribute to pathogenesis. Since it has also
become clear that many genetic disorders are not mono-
genic as originally supposed, but may instead involve
mutations in two or more genes, we speculate that different
combinations of pathological mutations with low pene-
trance, functional polymorphisms, disease susceptibility
variants and ‘putatively disadvantageous variants’ may
vary quite considerably in terms of their net functional and
hence clinical effect. Such combinations are likely to exert
an influence on the age of onset and/or clinical severity of
the disease in question.
The rationale of genetic studies of complex phenotypes
has generally relied upon either the ‘common disease,
common variant (CDCV)’ hypothesis or the ‘common
disease, rare variant (CDRV)’ hypothesis. The former
postulates that complex phenotypes result from the cumu-
lative effects of a number of common variants, each with a
modest effect size and relatively low penetrance. The latter
proposes that complex phenotypes result from multiple rare
variants, each with relatively high penetrance and large
effect sizes (Schork et al. 2009). It is highly likely that both
rare and common alleles will contribute to complex phe-
notypes and so effect sizes may be expected to differ quite
widely, with rare variants with large effects complemented
by a large number of frequent variants with small effects.
The clinical phenotypes of complex phenotypes are there-
fore likely to be due to individual effects of, and interaction
between, multiple causative or contributory alleles, as well
as non-genetic determinants.
The full relevance of digenic and oligogenic inheritance
to the phenomenon of incomplete or variable penetrance
remains to be elucidated. If, however, it turns out that di-
genic and oligogenic conditions are more common than
originally anticipated, then many disease contributory
variants will have evaded purifying selection, and hence
those variants that in combination (but not individually)
have significant pathogenic potential will not be as infre-
quent as might be expected under the CDRV hypothesis.
Since both multiple common and rare variants may be
involved in conferring disease susceptibility, we are not
obliged to favour either the CDCV hypothesis or the CDRV
hypothesis. Moreover, in view of the likely complexity of the
gene–gene interactions involved, we concur with Lupski et al.
(2011) that ‘‘for a given individual, what is important to know
is not only the number and location of pathogenic variants
taken one at a time, but also the unique composition of his or
her genome-wide mutational burden’’.
Lupski et al. (2011) charted progress on the road to a
unified genetic model for human disease and opined that
such a model should unite categories of diseases, previ-
ously held to be distinct entities, as part of a continuum
1102 Hum Genet (2013) 132:1077–1130
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which would include chromosomal syndromes, genomic
disorders, Mendelian traits and common diseases or com-
plex traits. Concurring with this view, we envisage an
integrated concept of genetic aetiology in which different
types of mutation (from single base substitutions to copy
number variants), different combinations of mutations in
multiple genes (whether in homozygosity or heterozygos-
ity), cis-acting or trans-acting modifiers, common variants,
rare variants, de novo variants and even somatic variants,
jointly serve to exacerbate or ameliorate a given clinical
phenotype. Further, to explain the scale of reduced pene-
trance, we need to conceptualize clinical phenotypes as
being derived, potentially at least, from the expression of
different genetic variants in two or more genes. On the
basis of the data collated for this review, it seems reason-
able to conclude that digenic, oligogenic and polygenic
influences are much more frequent than has perhaps hith-
erto been realized. Unravelling such influences will
undoubtedly be key to understanding the molecular basis of
reduced penetrance. The impact of disease genotypes may
also be modified by epigenetic and environmental factors,
allowing both for synergistic and antagonistic interactions
resulting in highly individualized contributions to the
phenotype (whether deleterious or protective) that will
variously perturb the balance of specific biological path-
ways so as to give rise to disease.
With the advent of next-generation sequencing, very
large numbers of genetic variants are being detected in
individual genomes and it has been necessary to develop
new algorithms to identify those variants which are of key
functional/clinical importance. However, if in using these
tools, we focus exclusively on single infrequent variants
under the assumption that they will invariably exert their
effects in splendid isolation, then there is a very real danger
that we shall inadvertently exclude from consideration
those more frequent variants with modest effects, blithely
ignoring their potential for interaction with the rare vari-
ants. The irony would then be that, despite having the
requisite mutation and polymorphism data available, the
molecular basis of genotype–phenotype relationships in
many inherited diseases (including, of course, the phe-
nomenon of reduced penetrance) could still remain unin-
telligible. The alternative, anticipating multigenic
influences on the clinical phenotypes associated with dis-
orders traditionally regarded as being monogenic, should
not only to lead to new insights into the nature of reduced
penetrance, but is also likely to improve our understanding
of the nature of complex disease.
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